10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-19-219949.txt : 20190813 0001193125-19-219949.hdr.sgml : 20190813 20190813160657 ACCESSION NUMBER: 0001193125-19-219949 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190813 DATE AS OF CHANGE: 20190813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Constellation Alpha Capital Corp. CENTRAL INDEX KEY: 0001651944 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38118 FILM NUMBER: 191020674 BUSINESS ADDRESS: STREET 1: EMERALD VIEW, SUITE 400 STREET 2: 2054 VISTA PARK CITY: WEST PALM BEACH STATE: FL ZIP: 33411 BUSINESS PHONE: (561) 404-9034 MAIL ADDRESS: STREET 1: EMERALD VIEW, SUITE 400 STREET 2: 2054 VISTA PARK CITY: WEST PALM BEACH STATE: FL ZIP: 33411 10-Q 1 d770326d10q.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2019

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 001-38118

CONSTELLATION ALPHA CAPITAL CORP.

(Exact name of registrant as specified in its charter)


British Virgin Islands		N/A
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

Emerald View, Suite 400 2054 Vista Parkway West Palm Beach, FL		33411
(Address of Principal Executive Offices)		(Zip Code)

(561) 404-9034

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one Ordinary Share, one Right and one Warrant	CNACU	The Nasdaq Stock Market LLC
Ordinary Shares, no par value	CNAC	The Nasdaq Stock Market LLC
Warrants, each Warrant entitling the holder to purchase one-half (¹/₂) of one Ordinary Share	CNACW	The Nasdaq Stock Market LLC
Rights, each Right entitling the holder to receive one-tenth (1/10) of one Ordinary Share	CNACR	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐.

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐.

As of August 13, 2019, 5,342,532 ordinary shares of the registrant were outstanding.

CONSTELLATION ALPHA CAPITAL CORP.

Quarterly Report on Form 10-Q

TABLE OF CONTENTS


		Page
PART I – FINANCIAL INFORMATION			1

Item 1.	Financial Statements		1

	Condensed Consolidated Balance Sheets		1

	Condensed Consolidated Statements of Operations		2

	Condensed Consolidated Statements of Changes in Shareholders’ Equity		3

	Condensed Consolidated Statements of Cash Flows		4

	Notes to Condensed Consolidated Financial Statements		5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		18

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		24

Item 4.	Controls and Procedures		24

PART II – OTHER INFORMATION			25

Item 1.	Legal Proceedings		25

Item 1A.	Risk Factors		25

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		25

Item 3.	Defaults Upon Senior Securities		25

Item 4.	Mine Safety Disclosures		25

Item 5.	Other Information		25

Item 6.	Exhibits		26

PART 1—FINANCIAL INFORMATION

Item 1. Financial Statements.

CONSTELLATION ALPHA CAPITAL CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS


	June 30, 2019		March 31, 2019
	(Unaudited)
Assets:
Current assets:
Cash	$	15,282	$	30,487
Prepaid expenses		45,750		51,257

Total current assets		61,032		81,744
Cash and marketable securities held in Trust Account		12,432,054		12,357,980

Total assets	$	12,493,086	$	12,439,724

Liabilities and Shareholders’ Equity:
Current liabilities:
Accounts payable and accrued expenses	$	2,353,005	$	1,522,158
Advances and notes payable		116,154		36,095

Total current liabilities		2,469,159		1,558,253
Deferred underwriting fees		4,312,500		5,031,250

Total liabilities		6,781,659		6,589,503
Commitments and Contingencies
Ordinary shares subject to possible redemption, 67,956 and 81,701 shares at redemption values as of June 30, 2019 and March 31, 2019, respectively		711,419		850,217
Shareholders’ Equity:
Preferred shares, no par value; unlimited shares authorized; none issued and outstanding		—		—
Ordinary shares, no par value; unlimited shares authorized; 5,274,576 and 5,260,831 shares issued and outstanding (excluding 67,956 and 81,701 shares subject to possible redemption) as of June 30, 2019 and March 31, 2019, respectively		3,340,730		3,201,932
Retained earnings		1,659,278		1,798,072

Total shareholders’ equity		5,000,008		5,000,004

Total Liabilities and Shareholders’ Equity	$	12,493,086	$	12,439,724

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

CONSTELLATION ALPHA CAPITAL CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)


	For the three months ended June 30,
	2019			2018
Operating costs	$	931,619		$	158,170

Loss from operations		(931,619	)		(158,170	)
Other income:
Interest income		70,855			649,640
Unrealized gain (loss) on marketable securities held in Trust Account		3,220			(47,682	)
Reduction of deferred underwriting fee		718,750			—

Net (loss) income	$	(138,794	)	$	443,788

Weighted average ordinary shares outstanding, basic and diluted ⁽¹⁾		5,260,831			5,091,071

Basic and diluted net loss per ordinary share	$	(0.03	)	$	(0.02	)

(1)

Excludes an aggregate of up to 67,956 and 13,427,259 shares subject to possible redemption at June 30, 2019 and 2018, respectively.

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

CONSTELLATION ALPHA CAPITAL CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(Unaudited)


	For the three months ended June 30, 2019
	Ordinary Shares								Total Shareholders’ Equity
	Shares		Amount			Retained Earnings			Total Shareholders’ Equity
Balance—March 31, 2019		5,260,831	$	3,201,932		$	1,798,072		$	5,000,004
Change in ordinary shares subject to possible redemption		13,745		138,798			—			138,798
Net income		—		—			(138,794	)		(138,794	)

Balance—June 30, 2019 (unaudited)		5,274,576	$	3,340,730		$	1,659,278		$	5,000,008


	For the three months ended June 30, 2018
	Ordinary Shares								Total Shareholders’ Equity
	Shares		Amount			Retained Earnings			Total Shareholders’ Equity
Balance—March 31, 2018		5,091,071	$	4,146,387		$	853,614		$	5,000,001
Change in ordinary shares subject to possible redemption		11,670		(443,788	)		—			(443,788	)
Net income		—		—			443,788			443,788

Balance—June 30, 2018 (unaudited)		5,102,741	$	3,702,599		$	1,297,402		$	5,000,001

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

CONSTELLATION ALPHA CAPITAL CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	For the three months ended June 30,
	2019			2018
Cash Flows from Operating Activities:
Net (loss) income	$	(138,794	)	$	443,788
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Interest earned on marketable securities held in Trust Account		(70,854	)		(649,640	)
Unrealized (gain) loss on securities held in Trust Account		(3,220	)		47,682
Reduction of deferred underwriting fee		(718,750	)		—
Changes in operating assets and liabilities:
Prepaid expenses		5,507			25,999
Accounts payable and accrued expenses		900,406			67,789

Net cash used in operating activities		(25,705	)		(64,382	)

Cash Flows from Financing Activities:
Advances received from related party		10,500			—

Net cash provided by financing activities		10,500			—

Net change in cash		(15,205	)		(64,382	)
Cash—Beginning		30,487			449,942

Cash—Ending	$	15,282		$	385,560

Non-Cash investing and financing activities:
Change in value of ordinary shares subject to possible redemption	$	138,798		$	443,788

Accounts payable paid by related party under the form of promissory notes	$	69,559		$	—

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

CONSTELLATION ALPHA CAPITAL CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS

Constellation Alpha Capital Corp. (the “Company” or “CNAC”) is a blank check company incorporated in the British Virgin Islands on July 31, 2015. The Company was formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation with, purchasing all or substantially all of the assets of, entering into contractual arrangements with, or engaging in any other similar business combination with one or more businesses or entities (“Business Combination”).

All activity through June 30, 2019 relates to the Company’s formation, its initial public offering consummated on June 23, 2017 (“Initial Public Offering”) of 14,375,000 units (“Units” and with respect to the ordinary shares included in the Units, the “Public Shares”), the sale of 561,250 units (the “Private Units”) in a private placement to the Company’s sponsor, Centripetal, LLC (the “Sponsor”) and Cowen Investments, LLC and their designees (“Cowen Investments”), and identifying a target company for a Business Combination. Each Unit consists of one Public Share, one right and one redeemable warrant (“Public Warrant”). Each right will convert into one-tenth (1/10) of one ordinary share. Each Public Warrant entitles the holder to purchase one-half (1/2) of one ordinary share at an exercise price of $11.50 per whole share.

The Company’s management has broad discretion with respect to the specific application of the net proceeds of its Initial Public Offering and Private Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. NASDAQ rules provide that the Company’s Business Combination must be with one or more target businesses that together have a fair market value equal to at least 80% of the balance in the trust account, which holds the proceeds from the Initial Public Offering and the sale of the Private Units (the “Trust Account”), (excluding any deferred underwriting commissions and taxes payable on interest earned on the Trust Account) at the time of the signing a definitive agreement in connection with a Business Combination. However, the Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended. There is no assurance that the Company will be able to successfully effect a Business Combination.

The Company will provide the holders of its Public Shares (“Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. In connection with a proposed Business Combination, the Company may seek shareholder approval of a Business Combination at a meeting called for such purpose at which shareholders may seek to redeem their shares, regardless of whether they vote for or against a Business Combination. The shareholders will be entitled to redeem their shares for a pro rata portion of the amount then in the Trust Account ($10.10 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to shareholders who redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6).

On March 21, 2019, at the Special Meeting, the Company’s shareholders approved the Company’s amended and restated memorandum and articles of association to extend the date by which the Company has to consummate a Business Combination (the “Extension”) to September 23, 2019 (the “Combination Period”). In connection with the Extension, an aggregate of 13,187,468 ordinary shares was redeemed for an aggregate payment of approximately $136.9 million out of the Trust Account.

If the Company is unable to complete a Business Combination on or before the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than five business days thereafter, redeem 100% of the outstanding Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned (net of taxes payable and less interest to pay dissolution expenses up to $50,000), divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the Company’s board

CONSTELLATION ALPHA CAPITAL CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject in each case to its obligations to provide for claims of creditors and the requirements of applicable law. The underwriters have agreed to waive their rights to the deferred underwriting commission held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Company’s Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution (including Trust Account assets) will be less than $10.10 per Unit. The Sponsor has agreed that it will indemnify the Company to the extent necessary to ensure that the proceeds in the Trust Account are not reduced by the claims of target businesses or claims of vendors or other entities that are owed money by the Company for services rendered or contracted for or products sold to the Company, but only if such a vendor or prospective target business does not execute such a waiver. However, the Sponsor may not be able to meet such obligation as the Company has not required its Sponsor to retain any assets to provide for its indemnification obligations, nor has the Company taken any further steps to ensure that the Sponsor will be able to satisfy any indemnification obligations that arise. Moreover, the Sponsor will not be liable to the Public Shareholders if it should fail to satisfy its obligations and instead will only be liable to the Company. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

On August 2, 2018, the Company entered into an agreement (“Share Purchase Agreement”) to purchase all of the issued and outstanding shares of capital stock of Medall Healthcare Private Limited, a company registered under the laws of India (“Medall”). On December 3, 2018, the Share Purchase Agreement was terminated automatically.

On March 15, 2019, the Company issued a press release announcing that it had executed a non-binding Letter of Intent to merge with DermTech, Inc. (“DermTech”), a Delaware corporation and a leading moleculargenomics company, with an initial focus on skin cancer, that develops and markets novel non-invasive diagnostic tests. On May 22, 2019 and May 23, 2019, the Company entered into separate subscription agreements (each an “Initial Subscription Agreement” and, collectively, the “Initial Subscription Agreements”), with new health care focused institutional investors as well as certain existing investors in DermTech (the “Initial Subscribers”), pursuant to which the Initial Subscribers agreed to purchase an aggregate of 6,153,847 shares (the “PIPE Shares”) of the Company’s common stock for a purchase price of $3.25 per share, in a private placement in which the Company will raise an aggregate of approximately $20 million, less certain offering related expenses payable by the Company (the “Private Placement”). The PIPE Shares are identical to the shares of common stock that will be held by the Company’s public stockholders at the time of the closing of the Merger, as defined below. The closing of the sale of PIPE Shares and the Preferred Shares will be contingent upon, among other things, the substantially concurrent consummation of the Merger.

On May 29, 2019, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with DermTech and DT Merger Sub, Inc., a wholly owned subsidiary company of the Company incorporated in Delaware (“Merger Sub”), pursuant to which the Company will re-domicile out of the British Virgin Islands and continue as a company incorporated in the State of Delaware and Merger Sub will merge with and into DermTech (the “Merger”), with DermTech surviving the Merger as a wholly owned subsidiary of the Company. Upon the closing of the Merger (the “Merger Closing”), all of DermTech’s outstanding common stock and preferred stock will be cancelled and converted automatically into the right to receive an aggregate of 16,000,000 shares of the Company less the total number of shares of the Company’s common stock that can be acquired or received pursuant to certain options, restricted stock units and warrants of DermTech, as set forth in the Merger Agreement. The Merger Agreement also provides that, prior to the Closing, Constellation will re-domicile out of the British Virgin Islands and continue as a company incorporated in the State of Delaware (Note 9).

On August 1, 2019, certain of the Initial Subscribers entered into amended and restated subscription agreements (the “Amended and Restated Subscription Agreements”) pursuant to which the Company agreed to sell to each such subscriber, and each such subscriber agreed to purchase, (i) shares of the Company’s common stock at a purchase price of $3.25 per share and (ii) shares of Series A Convertible Preferred Stock of the Company (the “Preferred Shares”) at a purchase price of $3,250 per Preferred Share. The subscribers to the Amended and Restated Subscription Agreements agreed to purchase an aggregate of 1,230,769 shares of the Company’s common stock and 1,231 Preferred Shares for an aggregate total purchase price of approximately $8 million. Pursuant to the terms of the Amended and Restated Subscription Agreements, each Preferred Share is convertible into 1,000 shares of the Company’s common stock. In connection with the New Subscription Agreement and the proposed issuance of Preferred Shares to certain subscribers, the Company received a waiver from DermTech to certain provisions of the Merger Agreement allowing the Company to (i) issue the Preferred Shares pursuant to the Amended and Restated Subscription Agreements and (ii) increase the amount of the proposed Private Placement to $24 million. On August 1, 2019, certain of the Initial Subscribers entered into an Omnibus Common Share Subscription Agreement Amendment, which modified certain of the Initial Subscription Agreements to, among other things, adjust the limitation on the aggregate proceeds that Constellation is permitted to receive from the sale of its stock from the date of the Merger Agreement from $20 million to $24 million.

On August 1, 2019, the Company entered into a subscription agreement (the “New Subscription Agreement”) with a new investor (the “New Subscriber”), pursuant to which the New Subscriber agreed to purchase, and the Company agreed to sell to the New Subscriber, an aggregate of 1,230,769 shares of the Company’s common stock, at a purchase price of $3.25 per share for a total purchase price of approximately $4 million. Under the New Subscription Agreement, the shares of the Company’s common stock to be issued and the price per share are subject to adjustment for any reverse split or other adjustment that may be effected for the purpose of meeting the initial listing requirements of the Nasdaq Capital Market in connection with the consummation of the Merger. The shares of the Company’s common stock to be issued pursuant to the New Subscription Agreement will be identical to the shares of the Company’s common stock that will be held by the Company’s public stockholders upon the closing of the Transaction.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

On February 22, 2019, the Company received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with Listing Rule 5550(a)(3) (the “Minimum Public Holders Rule”), which requires the Company to have at least 300 public holders for continued listing on the NASDAQ Capital Market. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the NASDAQ Capital Market.

CONSTELLATION ALPHA CAPITAL CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

On April 8, 2019, the Company submitted a plan to regain compliance with the Minimum Public Holders Rule to Nasdaq providing that it expects to regain compliance with the Minimum Public Holders Rule upon the consummation of the Merger. Nasdaq subsequently provided the Company with an extension until August 21, 2019, to demonstrate compliance with Nasdaq’s initial listing requirements.

Going Concern Consideration

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of June 30, 2019, the Company had cash held outside the Trust Account of approximately $15,000, cash and marketable securities held in the Trust Account of approximately $12.4 million (including approximately $438,000 of interest income, net of unrealized losses), substantially all of which is invested in U.S. treasury bills with a maturity of 180 days or less, and a working capital deficit of approximately $2.4 million. Further, the Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. Based on the foregoing, the Company will have insufficient funds available to operate its business through the earlier of consummation of a Business Combination or September 23, 2019. Following the initial Business Combination, if cash on hand is insufficient, the Company will need to obtain additional financing in order to meet its obligations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. The Company’s plans to raise capital or to consummate the initial Business Combination may not be successful. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended March 31, 2019 as filed with the SEC on June 14, 2019, which contains the audited consolidated financial statements and notes thereto. The financial information as of June 30, 2019 is derived from the audited consolidated financial statements presented in the Company’s Annual Report on Form 10-K for the year ended March 31, 2019. The interim results for the three months ended June 30, 2019 are not necessarily indicative of the results to be expected for the year ending March 31, 2020 or for any future interim periods.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.

CONSTELLATION ALPHA CAPITAL CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Emerging growth company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from our estimates.

Cash and cash equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of June 30, 2019 and March 31, 2019.

Cash and marketable securities held in Trust Account

At June 30, 2019 and March 31, 2019, the assets held in the Trust Account were substantially held in U.S. Treasury Bills.

Concentration of credit risk

Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which, at times may exceed the Federal depository insurance coverage of $250,000. The Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

CONSTELLATION ALPHA CAPITAL CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Fair value of financial instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the accompanying condensed consolidated balance sheets, primarily due to their short-term nature.

Ordinary shares subject to possible redemption

The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at June 30, 2019 and March 31, 2019, ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ equity section of the Company’s condensed consolidated balance sheets.

Net income (loss) per ordinary share

Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. The Company applies the two-class method in calculating earnings per share. Ordinary shares subject to possible redemption at June 30, 2019 and 2018, which are not currently redeemable and are not redeemable at fair value, have been excluded from the calculation of basic loss per share since such shares, if redeemed, only participate in their pro rata share of the earnings from the assets held in the Trust Account. The Company has not considered the effect of (1) warrants sold in the Initial Public Offering and private placement to purchase 7,468,125 ordinary shares, and (2) rights sold in the Initial Public Offering and private placement that convert into 1,493,625 ordinary shares, in the calculation of diluted loss per share, since the exercise of the warrants and the conversion of rights into ordinary shares is contingent upon the occurrence of future events. As a result, diluted loss per share is the same as basic loss per share for the periods.

Reconciliation of net (loss) income per ordinary share

The Company’s net (loss) income is adjusted for the portion of income that is attributable to ordinary shares subject to redemption, as these shares only participate in the income of the Trust Account and not the losses of the Company. Accordingly, basic and diluted net (loss) income per ordinary share is calculated as follows:


	For the three months ended June 30,
	2019			2018
Net income	$	(138,794	)	$	443,788
Less: Income attributable to ordinary shares subject to redemption		(4,237	)		(562,289	)

Adjusted net income (loss)	$	(143,031	)	$	(118,501	)

Weighted average ordinary shares outstanding, basic and diluted		5,260,831			5,091,071

Basic and diluted net income (loss) per ordinary share	$	(0.03	)	$	(0.02	)

CONSTELLATION ALPHA CAPITAL CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The calculation of income attributable to ordinary shares subject to redemption is as follows:


	For the three months ended June 30,
	2019			2018
Income attributable to ordinary shares subject to redemption:
Interest income and unrealized gains (losses)	$	74,075		$	601,958
Less:
(i) Company’s portion available to pay taxes		—			—
(ii) Company’s portion available to be withdrawn for working capital purposes		—			—

Subtotal		74,075			601,958
Ordinary shares subject to redemption		67,956			13,427,259
Total IPO shares		1,187,532			14,375,000
% Attributable to ordinary shares subject to redemption		5.72	%		93.41	%

Income Attributable to Ordinary Shares Subject to Redemption	$	4,237		$	562,289

Income taxes

The Company complies with the accounting and reporting requirements of ASC Topic 740, “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the British Virgin Islands is the Company’s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of June 30, 2019 and March 31, 2019, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.

The Company may be subject to potential examination by foreign taxing authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with foreign tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.

The Company’s tax provision is zero because the Company is organized in the British Virgin Islands with no connection to any other taxable jurisdiction. As such, the Company has no deferred tax assets. The Company is considered to be an exempted British Virgin Islands Company, and is presently not subject to income taxes or income tax filing requirements in the British Virgin Islands or the United States.

Recently issued accounting standards

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s condensed consolidated financial statements.

CONSTELLATION ALPHA CAPITAL CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

3. INITIAL PUBLIC OFFERING

On June 23, 2017, the Company sold 14,375,000 Units in the Initial Public Offering at a purchase price of $10.00 per Unit, which includes the full exercise by the underwriters of their over-allotment option in the amount of 1,875,000 Units at $10.00 per Unit. Each Unit consists of one ordinary share, one Public Right and one Public Warrant. Each Public Right will convert into one-tenth (1/10) of one ordinary share. Each Public Warrant entitles the holder to purchase one-half (¹/₂) of one ordinary share at an exercise price of $11.50 per whole share. The Company will not issue fractional shares.

4. PRIVATE PLACEMENT

Simultaneously with the Initial Public Offering, the Sponsor and Cowen Investments purchased an aggregate of 561,250 Private Units for an aggregate purchase price of $5,612,500, of which 425,000 Private Units were purchased by the Sponsor and 136,250 Private Units were purchased by Cowen Investments. The proceeds from the Private Units were added to the net proceeds from the Initial Public Offering held in the Trust Account.

The Private Units are identical to the Units sold in the Initial Public Offering, except for the Private Warrants, as described in Note 7. The holders have agreed not to transfer, assign or sell any of the Private Units or underlying securities (except to certain permitted transferees and provided the transferees agree to the same terms and restrictions as the permitted transferees of the founder shares must agree to) until after the completion of a Business Combination.

5. RELATED PARTY TRANSACTIONS

Administrative Services Arrangement

The Company entered into an agreement whereby, commencing on June 20, 2017 through the earlier of the Company’s consummation of a Business Combination and its liquidation, the Company pays the Sponsor a monthly fee of $10,000 for office space, utilities and administrative services. For the three months ended June 30, 2019 and 2018, the Company incurred $30,000 in fees for these services in each period. An aggregate of $100,000 and $70,000 in fees for these services were included in accounts payable and accrued expenses in the accompanying condensed consolidated balance sheets at June 30, 2019 and March 31, 2019, respectively.

Related Party Loans

In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of notes may be converted upon consummation of a Business Combination into additional Private Units at a price of $10.00 per Unit. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans.

As of March 31, 2018, the Company had an outstanding balance of approximately $11,100 of advances from related parties for expenses incurred on the Company’s behalf. In December 2018 and June 2019, the Company’s Chief Executive Officer (the “CEO”) advanced $25,000 and $10,500 to the Company, respectively. In addition, on April 17, 2019 and May 21, 2019, the Company entered into two promissory notes evidencing loans of $55,000 and $14,559 made to the Company by two lenders, respectively, for the sole purpose of paying a portion of the Company’s expenses. Subsequent to June 30, 2019, the Company received an additional advance of $24,500 from its CEO. The three advances were evidenced by promissory note for an aggregate principal amount of $60,000. The notes are non-interest bearing, unsecured and payable upon the consummation of the initial business combination. If the Company is unable to complete a business combination, the notes will be forgiven.

CONSTELLATION ALPHA CAPITAL CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

6. COMMITMENTS AND CONTINGENCIES

Registration Rights

Pursuant to a registration rights agreement entered into on June 19, 2017, the holders of the founder shares, Private Units and any units that may be issued upon conversion of the working capital loans (and underlying securities) are entitled to registration rights. The holders of 25% of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. However, the registration rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lock-up period. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

The underwriters are entitled to a deferred fee of up to three and one-half percent (3.5%) of the gross proceeds of the Initial Public Offering, of which 0.5% is payable solely at the discretion of the Company. In May 2019, the Company elected not to pay the 0.5% discretionary deferred underwriting fees to the underwriters. In connection with the execution of the Merger Agreement, CNAC, DermTech and Cowen and Company, LLC (“Cowen”) entered into a letter agreement, dated May 29, 2019, (the “Deferred Underwriting Fee Assignment Agreement”), pursuant to which CNAC agreed to assign to DermTech, and DermTech agreed to assume, CNAC’s obligation under the Underwriting Agreement, dated as of June 19, 2017 (the “Underwriting Agreement”), by and among CNAC and Cowen, acting as representative of the underwriters named in Schedule A thereto (the “Underwriters”), to pay the Underwriters the underwriting fee set forth therein (the “Underwriting Fee Assignment”), subject to certain adjustments and pursuant to the terms of the Deferred Underwriting Fee Assignment Agreement.

Pursuant to the terms of the Deferred Underwriting Fee Assignment Agreement, if the Merger is consummated and CNAC raises at least $15.0 million in proceeds from equity financings consummated prior to the one-year anniversary of the Merger Closing, excluding the proceeds received from any financing consummated prior to or simultaneous with the Merger Closing, then DermTech will pay to the underwriters $2,187,500 within two business days of CNAC receiving the proceeds from such equity financings. If CNAC fails to raise such funds by the one-year anniversary of the consummation of the Merger, then DermTech will pay to the Underwriters $1,093,750 within one week of the one-year anniversary of the Merger Closing, and the underwriters will have the option to receive an additional $1,093,750 in CNAC common stock at that time (the “Equity Payment”) based on the then fair market value of CNAC common stock, or to receive $1,093,750 in cash at a later date. DermTech’s payment to the Underwriters of $2,187,500, or its payment of $1,093,750 plus the Equity Payment, in either case, shall satisfy DermTech’s obligation to pay the deferred underwriting fees in full, and no further payment of any kind shall be required of DermTech or CNAC in connection with the deferred underwriting fees.

The Underwriting Fee Assignment will be effective only if and when the Merger is consummated; provided that the Underwriting Fee Assignment will not be effective in the event the Merger is consummated after September 23, 2019. CNAC has elected not to pay the 0.5% discretionary underwriting discount under the terms of the Underwriting Agreement.

7. SHAREHOLDERS’ EQUITY

Preferred Shares – The Company is authorized to issue an unlimited number of no par value preferred shares, divided into five classes, Class A through Class E, each with such designation, rights and preferences as may be determined by a resolution of the Company’s board of directors to amend the Memorandum and Articles of Association to create such designations, rights and preferences. The Company has five classes of preferred shares to give the Company flexibility as to the terms on which each Class is issued. All shares of a single class must be issued with the same rights and obligations. Accordingly, starting with five classes of preferred shares will allow the Company to issue shares at different times on different terms. At June 30, 2019 and March 31, 2019, there are no preferred shares designated, issued or outstanding.

Ordinary Shares – The Company is authorized to issue an unlimited number of no par value ordinary shares. Holders of the Company’s ordinary shares are entitled to one vote for each share. At June 30, 2019 and March 31, 2019, there were 5,274,576 and 5,260,831 ordinary shares issued and outstanding (excluding 67,956 and 81,701 ordinary shares subject to possible redemption, respectively).

CONSTELLATION ALPHA CAPITAL CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Simultaneously with the consummation of the Initial Public Offering in June 2017, the Sponsor forfeited 136,250 founder shares, which such shares were cancelled and simultaneously issued to Cowen Investments for no additional consideration (the “Cowen Shares”). The Company accounted for the Cowen Shares as an expense of the Initial Public Offering resulting in a charge directly to shareholders’ equity. The Company estimated the fair value of the Cowen Shares to be $1,362,500 based upon the offering price of the Units of $10.00 per Unit. Cowen Investments has agreed not to transfer, assign or sell any of the Cowen Shares (except to certain permitted transferees) until, with respect to 50% of the Cowen Shares, the earlier of (i) one year after the date of the consummation of a Business Combination, or (ii) the date on which the closing price of the Company’s ordinary shares equals or exceeds $12.50 per share for any 20 trading days within any 30- trading day period commencing after a Business Combination, and with respect to the remaining 50% of the Cowen Shares, upon one year after the date of the consummation of a Business Combination, or earlier, in each case, if, subsequent to a Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of the Company’s shareholders having the right to exchange their ordinary shares for cash, securities or other property. In addition, Cowen Investments has agreed (i) to waive its redemption rights with respect to such shares in connection with the completion of a Business Combination and (ii) to waive its rights to liquidating distributions from the Trust Account with respect to such shares if the Company fails to complete a Business Combination within the Combination Period.

Rights – Each holder of a right will receive one-tenth (1/10) of one ordinary share upon consummation of a Business Combination, even if the holder of such right redeemed all shares held by it in connection with a Business Combination. No fractional shares will be issued upon exchange of the rights. No additional consideration will be required to be paid by a holder of rights in order to receive its additional shares upon consummation of a Business Combination as the consideration related thereto has been included in the Unit purchase price paid for by investors in the Initial Public Offering. If the Company enters into a definitive agreement for a Business Combination in which the Company will not be the surviving entity, the definitive agreement will provide for the holders of rights to receive the same per share consideration the holders of the ordinary shares will receive in the transaction on an as-converted into ordinary share basis and each holder of a right will be required to affirmatively convert its rights in order to receive 1/10 share underlying each right (without paying additional consideration). The shares issuable upon exchange of the rights will be freely tradable (except to the extent held by affiliates of the Company).

If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of rights will not receive any of such funds with respect to their rights, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such rights, and the rights will expire worthless. Further, there are no contractual penalties for failure to deliver securities to the holders of the rights upon consummation of a Business Combination. Additionally, in no event will the Company be required to net cash settle the rights. Accordingly, the rights may expire worthless.

Warrants – Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the consummation of a Business Combination. No Public Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the ordinary shares issuable upon exercise of the Public Warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the ordinary shares issuable upon the exercise of the Public Warrants is not effective within 90 days from the consummation of a Business Combination, the holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise the Public Warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their Public Warrants on a cashless basis. The Public Warrants will expire five years from the consummation of a Business Combination or earlier upon redemption or liquidation.

CONSTELLATION ALPHA CAPITAL CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The Private Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except the Private Warrants are exercisable for cash (even if a registration statement covering the ordinary shares issuable upon exercise of such Private Warrants is not effective) or on a cashless basis, at the holder’s option, and are be redeemable by the Company, in each case so long as they are still held by the Initial Shareholders or their affiliates.

The Company may call the warrants for redemption (excluding the Private Warrants):

•

in whole and not in part;

•

at a price of $0.01 per warrant;

•

at any time while the Public Warrants are exercisable;

•

upon not less than 30 days’ prior written notice of redemption to each Public Warrant holder;

•

if, and only if, the reported last sale price of the ordinary shares equals or exceeds $18.00 per share, for any 20 trading days within a 30 trading day period ending on the third trading day prior to the notice of redemption to Public Warrant holders; and

•

if, and only if, there is a current registration statement in effect with respect to the ordinary shares underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.

If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement.

The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuances of ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless.

8. FAIR VALUE MEASUREMENTS

The Company follows the guidance in Accounting Standards Codification (“ASC”) 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually.

The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:


Level 1:		Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

CONSTELLATION ALPHA CAPITAL CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)


Level 2:		Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.

Level 3:		Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.

The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at June 30, 2019 and March 31, 2019, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:


Description	Level		June 30, 2019		March 31, 2019
Assets:
Marketable securities held in Trust Account		1	$	12,432,054	$	12,357,980

9. MERGER AGREEMENT

On May 29, 2019, the Company, Merger Sub, and DermTech entered into the Merger Agreement, which was amended on August 1, 2019, pursuant to which Merger Sub will merge with and into DermTech, with DermTech surviving the Merger as a wholly owned subsidiary of CNAC (collectively with the transactions related thereto, the “Transaction”).

Merger Agreement

Domestication

The Merger Agreement provides that at least two business days prior to the Merger Closing, CNAC will re-domicile out of the British Virgin Islands and continue as a company incorporated in the State of Delaware pursuant to Section 184 of the BVI Business Companies Act and Section 388 of the Delaware General Corporation Law (the “Domestication”). In connection with the Domestication, all ordinary shares of CNAC will be deemed to be converted into shares of common stock, par value $0.0001 per share, of CNAC (the “CNAC common stock”).

The Transaction and Consideration

At the Merger Closing, all of DermTech’s outstanding common stock and preferred stock will be cancelled and converted automatically into the right to receive an aggregate of 16,000,000 shares of CNAC common stock less the total number of shares of CNAC common stock that can be acquired or received pursuant to certain options, restricted stock units and warrants of DermTech, as set forth in the Merger Agreement. All of DermTech’s options, restricted stock units and warrants, whether vested or unvested, that will remain outstanding following the Merger Closing, will be assumed by CNAC and will become awards to acquire shares of CNAC common stock, as set forth in the Merger Agreement.

Conditions to Completion of the Transaction

Consummation of the Transaction is subject to customary and other conditions, including (i) the shareholders of CNAC having approved, among other things, the transactions contemplated by the Merger Agreement, (ii) the stockholders of DermTech having approved the transactions contemplated by the Merger Agreement, (iii) the completion of the Domestication, (iv) the absence of any governmental order that would prohibit the Transaction, and (v) a registration statement (as specified in the Merger Agreement) shall have been declared effective by the SEC.

Termination of the Merger Agreement

The Merger Agreement may be terminated prior to consummation of the Transaction by mutual consent of DermTech and CNAC. In addition, the Merger Agreement may be terminated by either DermTech or CNAC if (i) the Merger shall not have been consummated prior to September 24, 2019; (ii) any governmental authority in the United States shall have issued a final, non-appealable order that has the effect of making consummation of the Merger illegal

CONSTELLATION ALPHA CAPITAL CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

or otherwise preventing or prohibiting consummation of the Transaction; or (iii) the Merger Agreement shall fail to receive the requisite vote for approval when presented to CNAC’s shareholders. The Merger Agreement may also be terminated by either CNAC or DermTech in the event that certain other conditions provided for in the Merger Agreement are triggered.

Registration Rights Agreement

In connection with, and as a condition to the Merger Closing, the Merger Agreement provides that CNAC and certain persons and entities which will hold CNAC common stock upon the consummation of the Transaction (collectively, the “Investors”) will enter into a Registration Rights Agreement (the “Registration Rights Agreement”). Pursuant to the terms of the Registration Rights Agreement, CNAC will be obligated to file a shelf registration statement on Form S-3 to register the resale by the Investors of CNAC common stock issuable in connection with the Transaction. The Registration Rights Agreement will also provide the Investors with demand, “piggy-back” and Form S-3 registration rights, subject to certain minimum requirements and customary conditions.

Lock-Up Agreement

In connection with, and as a condition to the Merger Closing, the Merger Agreement provides that the Investors and certain persons and entities which will hold CNAC common stock upon the consummation of the Transaction will each enter into a Lock-up Agreement providing each such holder agrees that, during the period commencing on the Merger Closing and continuing to and including the date 180 days after the date of the Merger Closing, such holder will not sell, offer to sell, pledge, or transfer any CNAC securities held by such holder, subject to certain limited exceptions.

Subscription Agreements

On May 22, 2019 and May 23, 2019, CNAC entered into separate Subscription Agreements with new health care focused Subscribers, pursuant to which the Subscribers agreed to purchase, and CNAC agreed to sell to the Subscribers, an aggregate of 6,153,847 PIPE Shares, for a purchase price of $3.25 per share, in a private placement in which CNAC will raise an aggregate of approximately $20,000,000, less certain offering related expenses payable by CNAC. The PIPE Shares are identical to the shares of CNAC common stock that will be held by CNAC’s public stockholders at the time of the Merger Closing.

The closing of the sale of PIPE Closing will be contingent upon the substantially concurrent consummation of the Transaction. The PIPE Closing will occur on the date of, and immediately prior to, the consummation of the Transaction and will be subject to customary conditions. The purpose of the sale of the PIPE Shares is to raise additional capital for working capital following the Merger Closing.

CNAC has agreed that, within 45 days after the consummation of the Transaction, it will file with the SEC a registration statement registering the resale of the PIPE Shares, and will use its commercially reasonable efforts to have such registration statement declared effective as soon as practicable following the filing thereof.

No fees or other compensation was paid or will be payable to any of the Subscribers or any third parties in consideration of the Subscribers entering into the Subscription Agreements.

Forfeiture Agreement

On May 29, 2019, the Sponsor entered into a Forfeiture Letter, pursuant to which the Sponsor will forfeit to CNAC an aggregate of 2,694,779 shares of CNAC common stock, effective as of immediately prior to the consummation of the Transaction.

CONSTELLATION ALPHA CAPITAL CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

10. SUBSEQUENT EVENTS

New Subscription Agreement

On August 1, 2019, CNAC entered into the New Subscription Agreement with the New Subscriber, pursuant to which the New Subscriber agreed to purchase, and CNAC agreed to sell to the New Subscriber, an aggregate of 1,230,769 shares of CNAC common stock, at a purchase price of $3.25 per share for a total purchase price of approximately $4 million. Under the New Subscription Agreement, the shares of CNAC common stock to be issued and the price per share are subject to adjustment for any reverse split or other adjustment that may be effected for the purpose of meeting the initial listing requirements of the Nasdaq Capital Market in connection with the consummation of the Merger. The shares of CNAC common stock to be issued pursuant to the New Subscription Agreement will be identical to the shares of CNAC common stock that will be held by CNAC’s public stockholders upon the closing of the Merger.

The closing of the sale of CNAC common stock pursuant to the New Subscription Agreement will be contingent upon the consummation of the Merger and will occur concurrently with the closing of the Merger, subject to customary closing conditions. The purpose of the sale of CNAC common stock pursuant to the New Subscription Agreement is to raise additional capital for working capital for CNAC following the closing of the Merger.

CNAC has agreed that, within 45 days after the consummation of the Merger, it will file with the SEC a registration statement registering the resale of the CNAC common stock pursuant to the New Subscription Agreement, and will use its commercially reasonable efforts to have such registration statement declared effective as soon as practicable following the filing thereof.

Amended and Restated Subscription Agreements

On August 1, 2019, certain of the Initial Subscribers entered into the Amended and Restated Subscription Agreements pursuant to which CNAC agreed to sell to each such subscriber, and each such subscriber agreed to purchase, (i) PIPE shares at a purchase price of $3.25 per share and (ii) Preferred Shares at a purchase price of $3,250 per Preferred Share. The subscribers to the Amended and Restated Subscription Agreements agreed to purchase an aggregate of 1,230,769 shares of CNAC common stock and 1,231 Preferred Shares for an aggregate total purchase price of approximately $8 million. Pursuant to the terms of the Amended and Restated Subscription Agreements, each Preferred Share is convertible into 1,000 shares of CNAC common stock.

In connection with the closing of the Merger, CNAC will file a Certificate of Designation of Preferences, Rights and Limitations for the Preferred Shares (the “Series A Certificate of Designation”). Pursuant to the Series A Certificate of Designation, holders of the Preferred Shares will be entitled to receive dividends on an as-converted basis equal to and in the same form as dividends paid on shares of CNAC common stock when, as and if such dividends are paid on such common stock. The Series A Certificate of Designation will provide that holders of the Preferred Shares shall participate pari passu with the holders of CNAC common stock on an as-converted basis in the event of dissolution, liquidation or winding up of CNAC. The Series A Certificate of Designation also will provide that each Preferred Share will be convertible into CNAC common stock at a conversion price per share equal to $0.00325, provided that in no event shall any Preferred Shares be convertible if such conversion would result in the holder of such shares beneficially owning more than 9.99% of CNAC’s then-outstanding shares of common stock. The Preferred Shares shall have no voting rights, except with respect to certain protective provisions set forth in the Series A Certificate of Designation relating to the powers, preferences and rights of the Preferred Shares. The Preferred Shares will not be redeemable.

In connection with the New Subscription Agreement and the proposed issuance of Preferred Shares to certain subscribers, CNAC received a waiver from DermTech to certain provisions of the Merger Agreement allowing CNAC to (i) issue the Preferred Shares pursuant to the Amended and Restated Subscription Agreements and (ii) increase the amount of the proposed private placement to $24 million.

Omnibus Common Share Subscription Agreement Amendment

On August 1, 2019, certain of the Initial Subscribers entered into an Omnibus Common Share Subscription Agreement Amendment, which modified certain of the Initial Subscription Agreements to, among other things, adjust the limitation on the aggregate proceeds that CNAC is permitted to receive from the sale of its stock from the date of the Merger Agreement from $20 million to $24 million.

First Amendment to Agreement and Plan of Merger

On August 1, 2019, CNAC, Merger Sub, and DermTech, entered into the First Amendment to the Agreement and Plan of Merger, which amended the Merger Agreement to add Mr. Enrico Picozza to the list of initial directors of the combined company following the consummation of the Merger.

Related Party Loan

On August 7, 2019, the Company received an additional advance of $24,500 from its CEO, which was evidenced together with the advances received from the CEO in December 2018 and June 2019 by a promissory note for an aggregate principal amount $60,000.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

References in this report (the “Quarterly Report”) to “Constellation,” “we,” “us” or the “Company” refer to Constellation Alpha Capital Corp. References to our “management” or our “management team” refer to our officers and directors, and references to the “Sponsor” refer to Centripetal, LLC. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are not historical facts, and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements other than statements of historical fact included in this Form 10-Q including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding our financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”). Our securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Overview

We are a blank check company incorporated on July 31, 2015 in the British Virgin Islands and formed for the purpose of entering into a business combination with one or more target businesses.

On June 23, 2017, we consummated our initial public offering of 14,375,000 units (including 1,875,000 units sold pursuant to the underwriters exercising their over-allotment option), with each unit consisting of one ordinary share, one warrant, each warrant entitling the holder to purchase one-half of one ordinary share at a price of $11.50 per whole share and one right to receive one-tenth of one ordinary share upon the consummation of an initial business combination. No fractional shares will be issued upon exercise of the warrants. Each warrant will become exercisable on the completion of our business combination. The warrants will expire five years after the completion of our initial business combination or earlier upon redemption or liquidation.

The units in our initial public offering were sold at an offering price of $10.00 per unit, generating total gross proceeds of $143,750,000. Cowen Investments acted as the sole book running manager and I-Bankers Securities, Inc. acted as co-manager of the offering. The securities sold in the offering were registered under the Securities Act on a registration statement on Form S-1 (No. 333-218093), or our registration statement. The SEC declared our registration statement effective on June 19, 2017.

We paid a total of $2,875,000 in underwriting discounts and commissions and $514,467 for other costs and expenses related to our initial public offering. In addition, the underwriters agreed to defer $5,031,250 in underwriting discounts and commissions, and up to this amount will be payable upon consummation of the business combination. After deducting the underwriting discounts and commissions (excluding the deferred portion of $5,031,250 in underwriting discounts and commissions, which will be released from the trust account upon consummation of the business combination, if consummated) and the estimated offering expenses, the total net proceeds from our initial public offering and the private placement was $145,973,033, of which $145,187,500 (or $10.10 per unit sold in our initial public offering) was placed in the trust account. Of the 3.5% deferred underwriting fee, or $5,031,250, 0.5% (or $718,750) is payable in our sole discretion. In May 2019, we elected not to pay the 0.5% discretionary deferred underwriting fee to the underwriters.

In connection with the execution of the Merger Agreement, CNAC, DermTech and Cowen and Company, LLC (“Cowen”) entered into a letter agreement, dated May 29, 2019, (the “Deferred Underwriting Fee Assignment Agreement”), pursuant to which we agreed to assign to DermTech, and DermTech agreed to assume, our obligation under the Underwriting Agreement to pay the underwriters the deferred underwriting fees, subject to certain adjustments and pursuant to the terms of the Deferred Underwriting Fee Assignment Agreement.

Pursuant to the terms of the Deferred Underwriting Fee Assignment Agreement, if the Merger is consummated and we raise at least $15.0 million in proceeds from equity financings consummated prior to the one-year anniversary of the Merger Closing, excluding the proceeds received from any financing consummated prior to or simultaneous with the Merger Closing, then DermTech will pay to the underwriters $2,187,500 within two business days of CNAC receiving the proceeds from such equity financings. If we fail to raise such funds by the one-year anniversary of the consummation of the Merger, then DermTech will pay to the underwriters $1,093,750 within one week of the one-year anniversary of the Merger Closing, and the underwriters will have the option to receive an additional $1,093,750 in CNAC common stock at that time (the “Equity Payment”) based on the then fair market value of CNAC common stock, or to receive $1,093,750 in cash at a later date. DermTech’s payment to the underwriters of $2,187,500, or its payment of $1,093,750 plus the Equity Payment, in either case, shall satisfy DermTech’s obligation to pay the deferred underwriting fees in full, and no further payment of any kind shall be required of DermTech or CNAC in connection with the deferred underwriting fees.

On March 21, 2019, at the Special Meeting, our shareholders approved our amended and restated memorandum and articles of association to extend the date by which we have to consummate a business combination (the “Extension”) to September 23, 2019 (the “Combination Period”). In connection with the Extension, an aggregate of 13,187,468 ordinary shares was redeemed for an aggregate payment of approximately $136.9 million out of the trust account.

If we are unable to complete a Business Combination on or before the Combination Period, we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than five business days thereafter, redeem 100% of the outstanding public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned (net of taxes payable and less interest to pay dissolution expenses up to $50,000), divided by the number of then outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and our board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject in each case to our obligations to provide for claims of creditors and the requirements of applicable law.

We expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete a business combination or to raise capital will be successful.

On March 15, 2019, we issued a press release announcing that we executed a non-binding Letter of Intent to merge with DermTech, a Delaware corporation and a leading moleculargenomics company, with an initial focus on skin cancer, that develops and markets novel non-invasive diagnostic tests. On May 22, 2019 and May 23, 2019, we entered into separate subscription agreements (each, an “Initial Subscription Agreement” and collectively, the “Initial Subscription Agreements”), with new health care focused institutional investors as well as certain existing investors in DermTech (the “Initial Subscribers”), pursuant to which the Initial Subscribers agreed to purchase an aggregate of 6,153,847 shares (the “PIPE Shares”) of our common stock for a purchase price of $3.25 per share of common stock, in a private placement that contemplated that we would raise an aggregate of approximately $20 million, less certain offering related expenses payable by us (the “Private Placement”). The PIPE Shares are identical to the shares of common stock that will be held by our public stockholders at the time of the closing of the Merger, as defined below. The closing of the sale of PIPE Shares will be contingent upon, among other things, the substantially concurrent consummation of the Merger.

On May 29, 2019, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with DermTech and DT Merger Sub, Inc., our wholly owned subsidiary company of the Company incorporated in Delaware (“Merger Sub”), pursuant to which we will re-domicile out of the British Virgin Islands and continue as a company incorporated in the State of Delaware and Merger Sub will merge with and into DermTech (the “Merger”), with DermTech surviving the Merger as our wholly owned subsidiary. Upon the closing of the Merger, all of DermTech’s outstanding common stock and preferred stock will be cancelled and converted automatically into the right to receive an aggregate of 16,000,000 shares of the Company less the total number of shares of our common stock that can be acquired or received pursuant to certain options, restricted stock units and warrants of DermTech, as set forth in the Merger Agreement. Consummation of the Business Combination is subject to customary conditions.

On August 1, 2019, certain of the Initial Subscribers entered into amended and restated subscription agreements (the “Amended and Restated Subscription Agreements”) pursuant to which we agreed to sell to each such subscriber, and each such subscriber agreed to purchase, (i) shares of our common stock at a purchase price of $3.25 per share and (ii) shares of our Series A Convertible Preferred Stock (the “Preferred Shares”) at a purchase price of $3,250 per Preferred Share. The subscribers to the Amended and Restated Subscription Agreements agreed to purchase an aggregate of 1,230,769 shares of our common stock and 1,231 Preferred Shares for an aggregate total purchase price of approximately $8 million. Pursuant to the terms of the Amended and Restated Subscription Agreements, each Preferred Share is convertible into 1,000 shares of our common stock. In connection with the New Subscription Agreement and the proposed issuance of Preferred Shares to certain subscribers, we received a waiver from DermTech to certain provisions of the Merger Agreement allowing us to (i) issue the Preferred Shares pursuant to the Amended and Restated Subscription Agreements and (ii) increase the amount of the proposed Private Placement to $24 million. On August 1, 2019, certain of the Initial Subscribers entered into an Omnibus Common Share Subscription Agreement Amendment, which modified certain of the Initial Subscription Agreements to, among other things, adjust the limitation on the aggregate proceeds that Constellation is permitted to receive from the sale of its stock from the date of the Merger Agreement from $20 million to $24 million.

On August 1, 2019, we entered into a subscription agreement (the “New Subscription Agreement”) with a new investor (the “New Subscriber”), pursuant to which the New Subscriber agreed to purchase, and we agreed to sell to the New Subscriber, an aggregate of 1,230,769 shares of our common stock, at a purchase price of $3.25 per share for a total purchase price of approximately $4 million. Under the New Subscription Agreement, the shares of our common stock to be issued and the price per share are subject to adjustment for any reverse split or other adjustment that may be effected for the purpose of meeting the initial listing requirements of the Nasdaq Capital Market in connection with the consummation of the Merger. The shares of our common stock to be issued pursuant to the New Subscription Agreement will be identical to the shares of our common stock that will be held by our public stockholders upon the closing of the Merger.

In addition, on August 1, 2019, we entered into the First Amendment to the Agreement and Plan of Merger with Merger Sub, and DermTech, which amended the Merger Agreement to add Mr. Enrico Picozza to the list of initial directors of the combined company following the consummation of the Merger.

On August 8, 2019, the SEC declared effective our registration statement on Form S-4 (File No. 333-232181), as amended, which includes a proxy statement with respect to our special meeting of shareholders to approve the Merger Agreement among other matters as well as prospectus with respect to the shares of common stock to be issued in connection with the Merger. On August 9, 2019, we commenced the mailing of the proxy statement to our shareholders as of the July 25, 2019 record date.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

On February 22, 2019, the Notice from the Listing Qualifications Department of The Nasdaq Stock Market indicating that we are not in compliance with the Minimum Public Holders Rule, which requires us to have at least 300 public holders for continued listing on the NASDAQ Capital Market. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of our securities on the NASDAQ Capital Market.

On April 8, 2019, we submitted a plan to regain compliance with the Minimum Public Holders Rule to Nasdaq providing that it expects to regain compliance with the Minimum Public Holders Rule upon the consummation of the Merger. Nasdaq subsequently provided us with an extension until August 21, 2019, to demonstrate compliance with Nasdaq’s initial listing requirements.

Results of Operations

We have neither engaged in any operations nor generated any revenues to date. Our only activities from inception through June 30, 2019 were organizational activities, those necessary to consummate our initial public offering and identifying a target company for a business combination. We do not expect to generate any operating revenues until after the completion of our business combination. We expect to generate non-operating income in the form of interest income on cash and marketable securities we hold as a result of the initial public offering. We expect to incur increased expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses in pursuit of our acquisition plans.

For the three months ended June 30, 2019, we had net loss of approximately $139,000, consisting of interest income of approximately $70,900, unrealized gain on marketable securities held in our trust account of approximately $3,000, and reduction of deferred underwriting fees of approximately $719,000, offset by operating costs of approximately $932,000.

For the three months ended June 30, 2018, we had net income of approximately $444,000, consisting of interest income on marketable securities held in our trust account of approximately $650,000, offset by operating costs of approximately $158,000 and an unrealized loss on marketable securities held in our trust account of approximately $48,000.

Going Concern Consideration

The accompanying condensed consolidated financial statements have been prepared assuming we will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of June 30, 2019, we cash and marketable securities held in the trust account of approximately $12.4 million (including approximately $438,000 of interest income, net of unrealized losses), substantially all of which is invested in U.S. treasury bills with a maturity of 180 days or less, and a working capital deficit of approximately $2.4 million. Further, we have incurred and expect to continue to incur significant costs in pursuit of our acquisition plans. Based on the foregoing, we will have insufficient funds available to operate our business through the earlier of consummation of a business combination or September 23, 2019, the date we are required to liquidate the trust account and wind up our affairs if we have not completed a business combination. Following the initial business combination, if cash on hand is insufficient, we will need to obtain additional financing in order to meet our obligations. We cannot be certain that additional funding will be available on acceptable terms, or at all. Our plans to raise capital or to consummate the initial business combination may not be successful. These matters, among others, raise substantial doubt about our ability to continue as a going concern.

As of June 30, 2019, we had cash of approximately $15,000 held outside the trust account, which is available for use by us for general corporate purposes. In addition, as of June 30, 2019, we had accounts payable and accrued expenses of approximately $2.4 million.

On April 17, 2019 and May 21, 2019, we entered into two promissory notes evidencing loans of $55,000 and $14,559 made to us by two related parties, respectively, for the sole purpose of paying our expenses. The principal balance of the notes shall be payable on the date that we consummate our initial business combination from the funds available to us in connection with the consummation of our initial business combination.

Liquidity and Capital Resources

On June 23, 2017, we consummated our initial public offering of 14,375,000 Units, at a price of $10.00 per Unit, which includes the full exercise by the underwriters of their over-allotment option in the amount of 1,875,000 Units at $10.00 per Unit, generating gross proceeds of $143.75 million. Simultaneously with the closing of our initial public offering, we consummated the sale of 561,250 Private Units at a price of $10.00 per Unit, of which of which 425,000 Private Units were purchased by the Sponsor and 136,250 Private Units were purchased by Cowen Investments, generating gross proceeds of approximately $5.61 million.

Following the initial public offering and the exercise of the over-allotment option, a total of approximately $145.2 million was placed in the trust account. We incurred approximately $8.4 million in initial public offering related costs, including $2.875 million of underwriting fees, approximately $5.03 million of deferred underwriting fees and approximately $514,000 of initial public offering costs. In connection with the Extension in March 2019, an aggregate of 13,187,468 ordinary shares were redeemed for an aggregate payment of approximately $136.9 million out of the Trust Account.

For the three months ended June 30, 2019, cash used in operating activities amounted to approximately $26,000. Net income of approximately $2.0 million was impacted by interest earned on marketable securities held in the trust account of approximately $71,000, an unrealized gain on marketable securities held in the trust account of approximately $3,000, and reduction of deferred underwriting fees liability of approximately $719,000. Changes in our operating assets and liabilities provided cash of approximately $906,000. In addition, cash provided by financing activities was $10,500 comprised solely of advances from a related party.

For the three months ended June 30, 2018, cash used in operating activities amounted to approximately $64,000. Net income of approximately $444,000 was impacted by interest earned on marketable securities held in the trust account of approximately $650,000 and an unrealized loss on marketable securities held in the trust account of approximately $48,000. Changes in our operating assets and liabilities provided cash of approximately $94,000.

We intend to use substantially all of the net proceeds of our initial public offering and the sale of the private units, including the funds held in the trust account (excluding deferred underwriting commissions and taxes payable on interest earned on the trust account), to acquire a target business or businesses and to pay our expenses relating thereto. To the extent that our shares are used in whole or in part as consideration to effect our initial business combination, the remaining proceeds held in the trust account as well as any other net proceeds not expended will be used as working capital. Such working capital funds could be used in a variety of ways including continuing or expanding the target business’ operations, for strategic acquisitions and for marketing, research and development of existing or new products. Such funds could also be used to repay any operating expenses or finders’ fees which we had incurred prior to the completion of our initial business combination if the funds available to us outside of the trust account were insufficient to cover such expenses.

We intend to use the funds held outside the trust account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, and structure, negotiate and complete a business combination.

In order to finance transaction costs in connection with a business combination, our sponsor or an affiliate of our sponsor, or our officers and directors may, but are not obligated to, loan us funds as may be required. If we complete a business combination, we would repay such loaned amounts out of the proceeds of the trust account released to us. In the event that a business combination does not close, we may use a portion of the working capital held outside the trust account to repay such loaned amounts but no proceeds from our trust account would be used to repay such loaned amounts. Up to $1,500,000 of such loans may be converted into private units of the post business combination entity at a price of $10.00 per private unit at the option of the lender. The terms of such loans, if any, have not been determined and no written agreements exist with respect to such loans. As of March 31, 2018, we had an outstanding balance of approximately $11,100 of advances from related parties for expenses incurred on our behalf. In December 2018 and June 2019, our Chief Executive Officer (the “CEO”) advanced $25,000 and $10,500 to us, respectively. In addition, on April 17, 2019 and May 21, 2019, we entered into two promissory notes evidencing loans of $55,000 and $14,559 made to us by two lenders, respectively, for the sole purpose of paying a portion of our expenses. On August 7, 2019, we received an additional advance of $24,500 from our CEO, which were evidenced together with the advances received from the CEO in December 2018 and June 2019 by promissory note for an aggregate principal amount $60,000. The principal balance of the notes shall be payable on the date that we consummate our initial business combination from the funds available to us in connection with the consummation of our initial business combination.

We will need to obtain additional financing either to consummate our business combination or because we become obligated to redeem a significant number of our public shares upon consummation of our business combination, in which case we will issue additional securities or incur debt in connection with such business combination. Subject to compliance with applicable securities laws, we would only complete such financing simultaneously with the completion of our business combination, in which case we will issue additional securities or incur debt in connection with such business combination. We cannot provide any assurance that financing will be available to us on commercially acceptable terms, if at all. If we are unable to complete our business combination because we do not have sufficient funds available to us, we will be forced to cease operations and liquidate the trust account. In addition, following our business combination, if cash on hand is insufficient, we may need to obtain additional financing in order to meet our obligations.

Off-balance sheet financing arrangements

We have no obligations, assets or liabilities which would be considered off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

Contractual obligations

We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities, other than an agreement to pay our sponsor a monthly fee of $10,000 for office space, utilities and administrative support provided to the Company. We began incurring these fees on June 20, 2017 and will continue to incur these fees monthly until the earlier of the completion of the business combination and the Company’s liquidation.

Critical Accounting Policies

The preparation of condensed consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following critical accounting policy:

Ordinary shares subject to possible redemption

We account for our ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. Our ordinary shares feature certain redemption rights that are considered to be outside of our control and subject to occurrence of uncertain future events. Accordingly, at June 30, 2019 and March 31, 2019, ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ equity section of our condensed consolidated balance sheet.

Net income (loss) per ordinary share

Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. We apply the two-class method in calculating earnings per share. Ordinary shares subject to possible redemption at June 30, 2019 and 2018, which are not currently redeemable and are not redeemable at fair value, have been excluded from the calculation of basic loss per share since such shares, if redeemed, only participate in their pro rata share of the earnings from the assets held in the trust account.

Recent accounting pronouncements

The Merger

On May 29, 2019, the Company, Merger Sub, and DermTech entered into the Merger Agreement, which was amended on August 1, 2019, pursuant to which Merger Sub will merge with and into DermTech, with DermTech surviving the Merger as a wholly owned subsidiary of the Company (collectively with the transactions related thereto, the “Transaction”).

Merger Agreement

Domestication

The Merger Agreement provides that at least two business days prior to the closing of the Merger (the “Merger Closing”), we will re-domicile out of the British Virgin Islands and continue as a company incorporated in the State of Delaware pursuant to Section 184 of the BVI Business Companies Act and Section 388 of the Delaware General Corporation Law (the “Domestication”). In connection with the Domestication, all ordinary shares, no par value, of Constellation will be deemed to be converted into shares of common stock, par value $0.0001 per share, of Constellation (the “Constellation common stock”).

The Transaction and Consideration

At the Merger Closing, all of DermTech’s outstanding common stock and preferred stock will be cancelled and converted automatically into the right to receive an aggregate of 16,000,000 shares of Constellation common stock less the total number of shares of Constellation common stock that can be acquired or received pursuant to certain options, restricted stock units and warrants of DermTech, as set forth in the Merger Agreement. All of DermTech’s options, restricted stock units and warrants, whether vested or unvested, that will remain outstanding following the Merger Closing, will be assumed by Constellation and will become awards to acquire shares of Constellation common stock, as set forth in the Merger Agreement.

Conditions to Completion of the Transaction

Consummation of the Transaction is subject to customary and other conditions, including (i) the shareholders of Constellation having approved, among other things, the transactions contemplated by the Merger Agreement, (ii) the stockholders of DermTech having approved the transactions contemplated by the Merger Agreement, (iii) the completion of the Domestication, (iv) the absence of any governmental order that would prohibit the Transaction, and (v) a registration statement (as specified in the Merger Agreement) shall have been declared effective by the SEC.

Termination of the Merger Agreement

The Merger Agreement may be terminated prior to consummation of the Transaction by mutual consent of DermTech and Constellation. In addition, the Merger Agreement may be terminated by either DermTech or Constellation if (i) the Merger shall not have been consummated prior to September 24, 2019; (ii) any governmental authority in the United States shall have issued a final, non-appealable order that has the effect of making consummation of the Merger illegal or otherwise preventing or prohibiting consummation of the Transaction; or (iii) the Merger Agreement shall fail to receive the requisite vote for approval when presented to Constellation’s shareholders. The Merger Agreement may also be terminated by either Constellation or DermTech in the event that certain other conditions provided for in the Merger Agreement are triggered.

Registration Rights Agreement

In connection with, and as a condition to the Merger Closing, the Merger Agreement provides that Constellation and certain persons and entities which will hold Constellation common stock upon the consummation of the Transaction (collectively, the “Investors”) will enter into a Registration Rights Agreement (the “Registration Rights Agreement”). Pursuant to the terms of the Registration Rights Agreement, Constellation will be obligated to file a shelf registration statement on Form S-3 to register the resale by the Investors of Constellation common stock issuable in connection with the Transaction. The Registration Rights Agreement will also provide the Investors with demand, “piggy-back” and Form S-3 registration rights, subject to certain minimum requirements and customary conditions.

Lock-Up Agreement

In connection with, and as a condition to the Merger Closing, the Merger Agreement provides that the Investors and certain persons and entities which will hold Constellation common stock upon the consummation of the Transaction will each enter into a Lock-up Agreement providing each such holder agrees that, during the period commencing on the Merger Closing and continuing to and including the date 180 days after the date of the Merger Closing, such holder will not sell, offer to sell, pledge, or transfer any Constellation securities held by such holder, subject to certain limited exceptions.

Subscription Agreements

On May 22, 2019 and May 23, 2019, Constellation entered into separate Initial Subscription Agreements with certain of the Initial Subscribers, pursuant to which the Initial Subscribers agreed to purchase, and Constellation agreed to sell to the Initial Subscribers, an aggregate of 6,153,847 PIPE Shares for a purchase price of $3.25 per share, in a private placement which contemplated that Constellation would raise an aggregate of approximately $20,000,000, less certain offering related expenses payable by Constellation. The PIPE Shares are identical to the shares of Constellation common stock that will be held by Constellation’s public stockholders at the time of the Merger Closing.

The closing of the sale of PIPE Shares (the “PIPE Closing”) will be contingent upon the substantially concurrent consummation of the Transaction. The PIPE Closing will occur on the date of, and immediately prior to, the consummation of the Transaction and will be subject to customary conditions. The purpose of the sale of the PIPE Shares is to raise additional capital for working capital following the Merger Closing.

Constellation has agreed that, within 45 days after the consummation of the Transaction, it will file with the SEC a registration statement registering the resale of the PIPE Shares, and will use its commercially reasonable efforts to have such registration statement declared effective as soon as practicable following the filing thereof.

No fees or other compensation was paid or will be payable to any of the Subscribers or any third parties in consideration of the Subscribers entering into the Subscription Agreements.

On August 1, 2019, certain of the Initial Subscribers entered into the Amended and Restated Subscription Agreements pursuant to which we agreed to sell to each such subscriber, and each such subscriber agreed to purchase, (i) shares of our common stock at a purchase price of $3.25 per share and (ii) Preferred Shares at a purchase price of $3,250 per Preferred Share. The subscribers to the Amended and Restated Subscription Agreements agreed to purchase an aggregate of 1,230,769 shares of our common stock and 1,231 Preferred Shares for an aggregate total purchase price of approximately $8 million. Pursuant to the terms of the Amended and Restated Subscription Agreements, each Preferred Share is convertible into 1,000 shares of our common stock. In connection with the New Subscription Agreement and the proposed issuance of Preferred Shares to certain subscribers, we received a waiver from DermTech to certain provisions of the Merger Agreement allowing us to (i) issue the Preferred Shares pursuant to the Amended and Restated Subscription Agreements and (ii) increase the amount of the proposed Private Placement to $24 million. On August 1, 2019, certain of the Initial Subscribers entered into an Omnibus Common Share Subscription Agreement Amendment, which modified certain of the Initial Subscription Agreements to, among other things, adjust the limitation on the aggregate proceeds that Constellation is permitted to receive from the sale of its stock from the date of the Merger Agreement from $20 million to $24 million.

On August 1, 2019, we entered into the New Subscription Agreement with the New Subscriber, pursuant to which the New Subscriber agreed to purchase, and we agreed to sell to the New Subscriber, an aggregate of 1,230,769 shares of our common stock, at a purchase price of $3.25 per share for a total purchase price of approximately $4 million. Under the New Subscription Agreement, the shares of our common stock to be issued and the price per share are subject to adjustment for any reverse split or other adjustment that may be effected for the purpose of meeting the initial listing requirements of the Nasdaq Capital Market in connection with the consummation of the Merger. The shares of our common stock to be issued pursuant to the New Subscription Agreement will be identical to the shares of our common stock that will be held by our public stockholders upon the closing of the Merger.

Forfeiture Agreement

On May 29, 2019, the Sponsor entered into a Forfeiture Letter, pursuant to which the Sponsor will forfeit to Constellation an aggregate of 2,694,779 shares of Constellation common stock, effective as of immediately prior to the consummation of the Transaction.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

All activity through June 30, 2019 relates to our formation, the preparation for our Initial Public Offering and identifying a target company for a Business Combination. Following the consummation of our Initial Public Offering, the net proceeds of our Initial Public Offering were invested in U.S. government treasury bills with a maturity of 180 days or less. Due to the short-term nature of these investments, we do not believe that there will be an associated material exposure to interest rate risk at June 30, 2019.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Evaluation of Disclosure Controls and Procedures

As required by Rules 13a-15 and 15d-15 under the Exchange Act, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2019. Based upon their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective.

Changes in Internal Control Over Financial Reporting

During the most recently completed fiscal quarter, there has been no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

We are not currently a party to any material legal proceedings.

In June 2019, we received invoices for the payment of a placement and advisory commission and expenses totaling more than $1.2 million from a financial advisor pursuant to a letter agreement which was previously terminated by us. We do not believe any commissions are due and owing under the terms of the letter agreement.

ITEM 1A. RISK FACTORS.

Factors that could cause our actual results to differ materially from those in this Quarterly Report are any of the risks described in our Annual Report on Form 10-K for the year ended March 31, 2019 filed with the SEC. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended March 31, 2019 filed with the SEC, except as set forth in our Preliminary Proxy Statement on Schedule 14A filed with the SEC on October 3, 2018, as it may be amended from time to time, however, we may disclose changes to such risk factors or disclose additional risk factors from time to time in our future filings with the SEC.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS.

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.


No.		Description of Exhibit
31.1*		Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*		Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1**		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2**		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS*		XBRL Instance Document

101.SCH*		XBRL Taxonomy Extension Schema Document

101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*		XBRL Taxonomy Extension Labels Linkbase Document

101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

*	Filed herewith.

**	Furnished herewith.

SIGNATURES

Pursuant to the requirements of Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	CONSTELLATION ALPHA CAPITAL CORP.

Date: August 13, 2019		/s/ Rajiv Shukla
	Name:	Rajiv Shukla
	Title:	Chief Executive Officer (Principal Executive Officer)

Date: August 13, 2019		/s/ Craig Pollak
	Name:	Craig Pollak
	Title:	Chief Financial Officer (Principal Financial and Accounting Officer)

EX-31.1 2 d770326dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) and 15d-14(a), AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Rajiv Shukla, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Constellation Alpha Capital Corp.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-31.2 3 d770326dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) and 15d-14(a), AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Craig Pollak, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Constellation Alpha Capital Corp.;

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-32.1 4 d770326dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADDED BY

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Constellation Alpha Capital Corp. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2019, as filed with the Securities and Exchange Commission (the “Report”), I, Rajiv Shukla, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

EX-32.2 5 d770326dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADDED BY

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Constellation Alpha Capital Corp. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2019, as filed with the Securities and Exchange Commission (the “Report”), I, Craig Pollak, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

EX-101.INS 6 cnacu-20190630.xml XBRL INSTANCE DOCUMENT 0001651944 2019-04-01 2019-06-30 0001651944 2018-04-01 2018-06-30 0001651944 2019-06-30 0001651944 2019-03-31 0001651944 2018-06-30 0001651944 2017-05-20 2017-06-19 0001651944 2017-06-23 0001651944 2017-05-22 2017-06-23 0001651944 2017-05-19 2017-06-20 0001651944 2018-03-01 2018-03-31 0001651944 2019-03-01 2019-03-21 0001651944 2017-06-01 2017-06-30 0001651944 2019-08-13 0001651944 2018-03-31 0001651944 cnacu:PublicWarrantMember 2019-04-01 2019-06-30 0001651944 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001651944 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001651944 cnacu:PromissoryNotesMember 2019-04-01 2019-06-30 0001651944 srt:AffiliatedEntityMember 2019-04-01 2019-06-30 0001651944 cnacu:UnitsMember 2019-04-01 2019-06-30 0001651944 us-gaap:WarrantMember 2019-04-01 2019-06-30 0001651944 us-gaap:RightsMember 2019-04-01 2019-06-30 0001651944 cnacu:DeferredUnderwritingFeeAssignmentAgreementMember 2019-04-01 2019-06-30 0001651944 cnacu:DeferredUnderwritingFeeAssignmentAgreementMember cnacu:DermtechMember 2019-04-01 2019-06-30 0001651944 us-gaap:ChiefExecutiveOfficerMember 2019-04-01 2019-06-30 0001651944 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0001651944 cnacu:PromissoryNotesMember 2019-06-30 0001651944 us-gaap:AccountsPayableMember 2019-06-30 0001651944 cnacu:DermtechMember 2019-06-30 0001651944 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2019-03-31 0001651944 us-gaap:AccountsPayableMember 2019-03-31 0001651944 cnacu:PublicRightMember 2018-04-01 2018-06-30 0001651944 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001651944 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001651944 srt:AffiliatedEntityMember 2018-04-01 2018-06-30 0001651944 us-gaap:IPOMember 2017-05-22 2017-06-23 0001651944 us-gaap:OverAllotmentOptionMember 2017-05-22 2017-06-23 0001651944 us-gaap:PrivatePlacementMember 2017-05-22 2017-06-23 0001651944 cnacu:SponsorMember us-gaap:PrivatePlacementMember 2017-05-22 2017-06-23 0001651944 us-gaap:PrivatePlacementMember cnacu:CowenInvestmentMember 2017-05-22 2017-06-23 0001651944 us-gaap:IPOMember 2017-06-23 0001651944 us-gaap:OverAllotmentOptionMember 2017-06-23 0001651944 cnacu:IpoAndPrivatePlacementMember 2017-06-23 0001651944 cnacu:PipeSharesMember cnacu:SubscriptionAgreementMember 2019-05-01 2019-05-22 0001651944 cnacu:SubscriptionAgreementMember cnacu:PipeSharesMember 2019-05-22 0001651944 cnacu:CowenInvestmentsIiLlcMember us-gaap:CommercialPaperMember 2019-05-21 0001651944 us-gaap:CommercialPaperMember 2019-05-21 0001651944 cnacu:CowenInvestmentMember 2017-06-01 2017-06-30 0001651944 cnacu:CowenSharesAgreementMember 2017-06-30 0001651944 us-gaap:WarrantsAndRightsSubjectToMandatoryRedemptionMember 2017-06-30 0001651944 cnacu:PipeSharesMember 2019-05-29 2019-06-30 0001651944 cnacu:DermtechMember 2019-05-29 2019-05-29 0001651944 us-gaap:CommercialPaperMember 2019-04-17 0001651944 cnacu:CowenInvestmentsIiLlcMember us-gaap:CommercialPaperMember 2019-04-17 0001651944 cnacu:PipeSharesMember us-gaap:SubsequentEventMember cnacu:AmendedAndRestatedSubscriptionAgreementMember 2019-08-01 0001651944 us-gaap:SubsequentEventMember cnacu:AmendedAndRestatedSubscriptionAgreementMember us-gaap:ConvertiblePreferredStockMember 2019-08-01 0001651944 us-gaap:SubsequentEventMember cnacu:NewSubscriptionAgreementMember us-gaap:CommonStockMember 2019-08-01 0001651944 cnacu:AmendedAndRestatedSubscriptionAgreementMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2019-08-01 0001651944 cnacu:AmendedAndRestatedSubscriptionAgreementMember us-gaap:SubsequentEventMember 2019-08-01 0001651944 us-gaap:ChiefExecutiveOfficerMember 2018-01-01 2018-12-31 0001651944 us-gaap:SubsequentEventMember cnacu:AmendedAndRestatedSubscriptionAgreementMember 2019-08-01 2019-08-01 0001651944 us-gaap:SubsequentEventMember cnacu:NewSubscriptionAgreementMember us-gaap:CommonStockMember 2019-08-01 2019-08-01 0001651944 us-gaap:SubsequentEventMember cnacu:AmendedAndRestatedSubscriptionAgreementMember cnacu:ModificationToAgreementMember srt:MinimumMember 2019-08-01 2019-08-01 0001651944 us-gaap:SubsequentEventMember cnacu:AmendedAndRestatedSubscriptionAgreementMember cnacu:ModificationToAgreementMember srt:MaximumMember 2019-08-01 2019-08-01 0001651944 us-gaap:CommonStockMember us-gaap:SubsequentEventMember cnacu:AmendedAndRestatedSubscriptionAgreementMember 2019-08-01 2019-08-01 0001651944 us-gaap:ConvertiblePreferredStockMember us-gaap:SubsequentEventMember cnacu:AmendedAndRestatedSubscriptionAgreementMember 2019-08-01 2019-08-01 0001651944 us-gaap:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2019-08-07 2019-08-07 0001651944 us-gaap:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2019-08-07 0001651944 us-gaap:CommonStockMember 2019-03-31 0001651944 us-gaap:RetainedEarningsMember 2019-03-31 0001651944 us-gaap:CommonStockMember 2019-06-30 0001651944 us-gaap:RetainedEarningsMember 2019-06-30 0001651944 us-gaap:CommonStockMember 2018-03-31 0001651944 us-gaap:RetainedEarningsMember 2018-03-31 0001651944 us-gaap:CommonStockMember 2018-06-30 0001651944 us-gaap:RetainedEarningsMember 2018-06-30

15282

30487

45750

51257

61032

81744

12432054

12357980

12493086

12439724

2353005

1522158

2469159

1558253

4312500 5031250

6781659

6589503

711419

850217

3340730

3201932

1659278

1798072

5000008

12493086

12439724

561250

50000

250000

7468125

1493625

-138794

443788

-4237

-562289

-143031

-118501

-0.03

-0.02

14375000

10.00

1875000

10.00

11.50

5612500

425000

136250

931619

158170

-931619

-158170

70855

649640

5260831

5091071

70854

649640

3220

-47682

-5507

-25999

900406

67789

5260831

3201932

1798072

5000004

13745

-138798

-138794

5274576

3340730

1659278

11670

443788

5102741

3702599

1297402

5000001

5091071

4146387

853614

5000001

10000

1500000

10.00

67956

81701

12432054 12357980

-25705

-64382

10500

-15205

-64382

449942

385560

138798 443788

13187468

136900000

6153847

3.25

15000

438000

2400000

30000

100000

70000

14559

136250

1362500

12.50

<div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basis of presentation </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 10 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> of the Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended March 31, 2019 as filed with the SEC on June 14, 2019, which contains the audited consolidated financial statements and notes thereto. The financial information as of June 30, 2019 is derived from the audited consolidated financial statements presented in the Company’s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended March 31, 2019. The interim results for the three months ended June 30, 2019 are not necessarily indicative of the results to be expected for the year ending March 31, 2020 or for any future interim periods.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: "times new roman"; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Emerging growth company </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">to non-emerging growth</div> companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net income (loss) per ordinary share </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. The Company applies <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the two-class method</div> in calculating earnings per share. Ordinary shares subject to possible redemption at June 30, 2019 and 2018, which are not currently redeemable and are not redeemable at fair value, have been excluded from the calculation of basic loss per share since such shares, if redeemed, only participate in their pro rata share of the earnings from the assets held in the Trust Account. The Company has not considered the effect of (1) warrants sold in the Initial Public Offering and private placement to purchase 7,468,125 ordinary shares, and (2) rights sold in the Initial Public Offering and private placement that convert into 1,493,625 ordinary shares, in the calculation of diluted loss per share, since the exercise of the warrants and the conversion of rights into ordinary shares is contingent upon the occurrence of future events. As a result, diluted loss per share is the same as basic loss per share for the periods.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reconciliation of net (loss) income per ordinary share </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company’s net (loss) income is adjusted for the portion of income that is attributable to ordinary shares subject to redemption, as these shares only participate in the income of the Trust Account and not the losses of the Company. Accordingly, basic and diluted net (loss) income per ordinary share is calculated as follows: </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px; background: none;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="padding: 0px;;width:74%;"></td><td style="padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">For the three months ended June 30,</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net income</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(138,794</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">443,788</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Less: Income attributable to ordinary shares subject to redemption</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">(4,237</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">(562,289</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Adjusted net income (loss)</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(143,031</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(118,501</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Weighted average ordinary shares outstanding, basic and diluted</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">5,260,831</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">5,091,071</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Basic and diluted net income (loss) per ordinary share</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(0.03</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(0.02</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">) </div></td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="font-size: 1px; margin-top: 0px; margin-bottom: 0px; background: none;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The calculation of income attributable to ordinary shares subject to redemption is as follows: </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px; background: none;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="padding: 0px;;width:72%;"></td><td style="padding: 0px;;vertical-align:bottom;;width:8%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:7%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">For the three months ended June 30,</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">Income attributable to ordinary shares subject to redemption:</div></div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Interest income and unrealized gains (losses)</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">74,075</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">601,958</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Less:</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(i) Company’s portion available to pay taxes</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(ii) Company’s portion available to be withdrawn for working capital purposes</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subtotal</div></div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">74,075</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">601,958</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Ordinary shares subject to redemption</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">67,956</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">13,427,259</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total IPO shares</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">1,187,532</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">14,375,000</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">% Attributable to ordinary shares subject to redemption</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5.72</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">% </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">93.41</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">% </td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income Attributable to Ordinary Shares Subject to Redemption</div></div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">4,237</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">562,289</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Accordingly, basic and diluted net (loss) income per ordinary share is calculated as follows:<table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px; background: none;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="padding: 0px;;width:74%;"></td><td style="padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">For the three months ended June 30,</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net income</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(138,794</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">443,788</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Less: Income attributable to ordinary shares subject to redemption</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">(4,237</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">(562,289</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Adjusted net income (loss)</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(143,031</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(118,501</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Weighted average ordinary shares outstanding, basic and diluted</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">5,260,831</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">5,091,071</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Basic and diluted net income (loss) per ordinary share</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(0.03</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(0.02</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">) </div></td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

81701

Each Unit consists of one Public Share, one right and one redeemable warrant (“Public Warrant”). Each right will convert into one-tenth (1/10) of one ordinary share. Each Public Warrant entitles the holder to purchase one-half (1/2) of one ordinary share at an exercise price of $11.50 per whole share.

10.10

5274576

5260831

0.01 Cowen Investments has agreed not to transfer, assign or sell any of the Cowen Shares (except to certain permitted transferees) until, with respect to 50% of the Cowen Shares, the earlier of (i) one year after the date of the consummation of a Business Combination, or (ii) the date on which the closing price of the Company’s ordinary shares equals or exceeds $12.50 per share for any 20 trading days within any 30- trading day period commencing after a Business Combination, and with respect to the remaining 50% of the Cowen Shares, upon one year after the date of the consummation of a Business Combination, or earlier, in each case, if, subsequent to a Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of the Company’s shareholders having the right to exchange their ordinary shares for cash, securities or other property. 718750 0

67956

13427259

69559 0 Yes FL 5342532 Yes Units, each consisting of one Ordinary Share, one Right and one Warrant Ordinary Shares Warrants, each Warrant entitling the holder to purchase one-half (1/2) of one Ordinary Share Rights, each Right entitling the holder to receive one-tenth (1/10) of one Ordinary Share CNACU CNAC CNACW CNACR NASDAQ NASDAQ NASDAQ NASDAQ <div style="font-family: "times new roman"; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The calculation of income attributable to ordinary shares subject to redemption is as follows: </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px; background: none;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="padding: 0px;;width:72%;"></td><td style="padding: 0px;;vertical-align:bottom;;width:8%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:7%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">For the three months ended June 30,</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">Income attributable to ordinary shares subject to redemption:</div></div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Interest income and unrealized gains (losses)</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">74,075</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">601,958</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Less:</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(i) Company’s portion available to pay taxes</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(ii) Company’s portion available to be withdrawn for working capital purposes</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subtotal</div></div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">74,075</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">601,958</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Ordinary shares subject to redemption</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">67,956</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">13,427,259</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total IPO shares</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">1,187,532</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">14,375,000</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">% Attributable to ordinary shares subject to redemption</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5.72</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">% </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">93.41</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">% </td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income Attributable to Ordinary Shares Subject to Redemption</div></div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">4,237</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">562,289</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 74075 601958

0 0 74075 601958 1187532 14375000 4237 562289

6153847

20000000

2694779

16000000

5.72 93.41

5612500

14559

55000

Each holder of a right will receive one-tenth (1/10) of one ordinary share upon consummation of a Business Combination, even if the holder of such right redeemed all shares held by it in connection with a Business Combination.

5612500

-0.035

15000000

2187500 Pursuant to the terms of the Deferred Underwriting Fee Assignment Agreement, if the Merger is consummated and CNAC raises at least $15.0 million in proceeds from equity financings consummated prior to the one-year anniversary of the Merger Closing, excluding the proceeds received from any financing consummated prior to or simultaneous with the Merger Closing, then DermTech will pay to the underwriters $2,187,500 within two business days of CNAC receiving the proceeds from such equity financings. If CNAC fails to raise such funds by the one-year anniversary of the consummation of the Merger, then DermTech will pay to the Underwriters $1,093,750 within one week of the one-year anniversary of the Merger Closing, and the underwriters will have the option to receive an additional $1,093,750 in CNAC common stock at that time (the "Equity Payment") based on the then fair market value of CNAC common stock, or to receive $1,093,750 in cash at a later date. DermTech's payment to the Underwriters of $2,187,500, or its payment of $1,093,750 plus the Equity Payment, in either case, shall satisfy DermTech's obligation to pay the deferred underwriting fees in full, and no further payment of any kind shall be required of DermTech or CNAC in connection with the deferred underwriting fees.

30000

11100

25000

10500

60000

24500

116154

36095

<div style="margin: 0in 0in 0.0001pt; font-family: "times new roman", serif; font-size: 10pt;"><div style="font-weight:bold;display:inline;">6. COMMITMENTS AND CONTINGENCIES</div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Registration Rights </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Pursuant to a registration rights agreement entered into on June 19, 2017, the holders of the founder shares, Private Units and any units that may be issued upon conversion of the working capital loans (and underlying securities) are entitled to registration rights. The holders of 25% of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. However, the registration rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">applicable lock-up period.</div> The Company will bear the expenses incurred in connection with the filing of any such registration statements.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Underwriting Agreement </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The underwriters are entitled to a deferred fee of up to three <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and one-half percent </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3.5</div>%</div>) </div>of the gross proceeds of the Initial Public Offering, of which 0.5% is payable solely at the discretion of the Company. In May 2019, the Company elected not to pay the 0.5% discretionary deferred underwriting fees to the underwriters. In connection with the execution of the Merger Agreement, CNAC, DermTech and Cowen and Company, LLC (“Cowen”) entered into a letter agreement, dated May 29, 2019, (the “Deferred Underwriting Fee Assignment Agreement”), pursuant to which CNAC agreed to assign to DermTech, and DermTech agreed to assume, CNAC’s obligation under the Underwriting Agreement, dated as of June 19, 2017 (the “Underwriting Agreement”), by and among CNAC and Cowen, acting as representative of the underwriters named in Schedule A thereto (the “Underwriters”), to pay the Underwriters the underwriting fee set forth therein (the “Underwriting Fee Assignment”), subject to certain adjustments and pursuant to the terms of the Deferred Underwriting Fee Assignment Agreement.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the terms of the Deferred Underwriting Fee Assignment Agreement, if the Merger is consummated and CNAC raises at least $15.0 million in proceeds from equity financings consummated prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> anniversary of the Merger Closing, excluding the proceeds received from any financing consummated prior to or simultaneous with the Merger Closing, then DermTech will pay to the underwriters $2,187,500 within two business days of CNAC receiving the proceeds from such equity financings. If CNAC fails to raise such funds by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> anniversary of the consummation of the Merger, then DermTech will pay to the Underwriters $1,093,750 within one week of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> anniversary of the Merger Closing, and the underwriters will have the option to receive an additional $1,093,750 in CNAC common stock at that time (the “Equity Payment”) based on the then fair market value of CNAC common stock, or to receive $1,093,750 in cash at a later date. DermTech’s payment to the Underwriters of $2,187,500, or its payment of $1,093,750 plus the Equity Payment, in either case, shall satisfy DermTech’s obligation to pay the deferred underwriting fees in full, and no further payment of any kind shall be required of DermTech or CNAC in connection with the deferred underwriting fees.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Underwriting Fee Assignment will be effective only if and when the Merger is consummated; provided that the Underwriting Fee Assignment will not be effective in the event the Merger is consummated after September 23, 2019</div>. CNAC has elected not to pay the 0.5% discretionary underwriting discount under the terms of the Underwriting Agreement. <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at June 30, 2019 and March 31, 2019, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px; background: none;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"><tr style="font-size: 0px;"><td style="padding: 0px;;width:67%;"></td><td style="padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"><div style="font-family: "times new roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description</div></div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June 30, 2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">March 31, 2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Assets:</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in Trust Account</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">1</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">12,432,054</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">12,357,980</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10. SUBSEQUENT EVENTS </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">New Subscription Agreement </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On August 1, 2019, CNAC entered into the New Subscription Agreement with the New Subscriber, pursuant to which the New Subscriber agreed to purchase, and CNAC agreed to sell to the New Subscriber, an aggregate of 1,230,769 shares of CNAC common stock, at a purchase price of $3.25 per share for a total purchase price of approximately $4 million. Under the New Subscription Agreement, the shares of CNAC common stock to be issued and the price per share are subject to adjustment for any reverse split or other adjustment that may be effected for the purpose of meeting the initial listing requirements of the Nasdaq Capital Market in connection with the consummation of the Merger. The shares of CNAC common stock to be issued pursuant to the New Subscription Agreement will be identical to the shares of CNAC common stock that will be held by CNAC’s public stockholders upon the closing of the Merger. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The closing of the sale of CNAC common stock pursuant to the New Subscription Agreement will be contingent upon the consummation of the Merger and will occur concurrently with the closing of the Merger, subject to customary closing conditions. The purpose of the sale of CNAC common stock pursuant to the New Subscription Agreement is to raise additional capital for working capital for CNAC following the closing of the Merger. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">CNAC has agreed that, within 45 days after the consummation of the Merger, it will file with the SEC a registration statement registering the resale of the CNAC common stock pursuant to the New Subscription Agreement, and will use its commercially reasonable efforts to have such registration statement declared effective as soon as practicable following the filing thereof. </div><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Amended and Restated Subscription Agreements </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On August 1, 2019, certain of the Initial Subscribers entered into the Amended and Restated Subscription Agreements pursuant to which CNAC agreed to sell to each such subscriber, and each such subscriber agreed to purchase, (i) PIPE shares at a purchase price of $3.25 per share and (ii) Preferred Shares at a purchase price of $3,250 per Preferred Share. The subscribers to the Amended and Restated Subscription Agreements agreed to purchase an aggregate of 1,230,769 shares of CNAC common stock and 1,231 Preferred Shares for an aggregate total purchase price of approximately $8 million. Pursuant to the terms of the Amended and Restated Subscription Agreements, each Preferred Share is convertible into 1,000 shares of CNAC common stock. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the closing of the Merger, CNAC will file a Certificate of Designation of Preferences, Rights and Limitations for the Preferred Shares (the “Series A Certificate of Designation”). Pursuant to the Series A Certificate of Designation, holders of the Preferred Shares will be entitled to receive dividends on an as-converted basis equal to and in the same form as dividends paid on shares of CNAC common stock when, as and if such dividends are paid on such common stock. The Series A Certificate of Designation will provide that holders of the Preferred Shares shall participate pari passu with the holders of CNAC common stock on an as-converted basis in the event of dissolution, liquidation or winding up of CNAC. The Series A Certificate of Designation also will provide that each Preferred Share will be convertible into CNAC common stock at a conversion price per share equal to $0.00325, provided that in no event shall any Preferred Shares be convertible if such conversion would result in the holder of such shares beneficially owning more than 9.99% of CNAC’s then-outstanding shares of common stock. The Preferred Shares shall have no voting rights, except with respect to certain protective provisions set forth in the Series A Certificate of Designation relating to the powers, preferences and rights of the Preferred Shares. The Preferred Shares will not be redeemable. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the New Subscription Agreement and the proposed issuance of Preferred Shares to certain subscribers, CNAC received a waiver from DermTech to certain provisions of the Merger Agreement allowing CNAC to (i) issue the Preferred Shares pursuant to the Amended and Restated Subscription Agreements and (ii) increase the amount of the proposed private placement to $24 million. </div><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Omnibus Common Share Subscription Agreement Amendment </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On August 1, 2019, certain of the Initial Subscribers entered into an Omnibus Common Share Subscription Agreement Amendment, which modified certain of the Initial Subscription Agreements to, among other things, adjust the limitation on the aggregate proceeds that CNAC is permitted to receive from the sale of its stock from the date of the Merger Agreement from $20 million to $24 million. </div><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">First Amendment to Agreement and Plan of Merger </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On August 1, 2019, CNAC, Merger Sub, and DermTech, entered into the First Amendment to the Agreement and Plan of Merger, which amended the Merger Agreement to add Mr. Enrico Picozza to the list of initial directors of the combined company following the consummation of the Merger. </div><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Related Party Loan </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On August 7, 2019, the Company received an additional advance of $24,500 from its CEO, which was evidenced together with the advances received from the CEO in December 2018 and June 2019 by a promissory note for an aggregate principal amount $60,000. </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Constellation Alpha Capital Corp. (the “Company” or “CNAC”) is a blank check company incorporated in the British Virgin Islands on July 31, 2015. The Company was formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation with, purchasing all or substantially all of the assets of, entering into contractual arrangements with, or engaging in any other similar business combination with one or more businesses or entities (“Business Combination”). </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">All activity through June 30, 2019 relates to the Company’s formation, its initial public offering consummated on June 23, 2017 (“Initial Public Offering”) of 14,375,000 units (“Units” and with respect to the ordinary shares included in the Units, the “Public Shares”), the sale of 561,250 units (the “Private Units”) in a private placement to the Company’s sponsor, Centripetal, LLC (the “Sponsor”) and Cowen Investments, LLC and their designees (“Cowen Investments”), and identifying a target company for a Business Combination. Each Unit consists of one Public Share, one right and one redeemable warrant (“Public Warrant”). Each right will convert <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">into one-tenth (1/10)</div> of one ordinary share. Each Public Warrant entitles the holder to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">purchase one-half (1/2)</div> of one ordinary share at an exercise price of $11.50 per whole share.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company’s management has broad discretion with respect to the specific application of the net proceeds of its Initial Public Offering and Private Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. NASDAQ rules provide that the Company’s Business Combination must be with one or more target businesses that together have a fair market value equal to at least 80% of the balance in the trust account, which holds the proceeds from the Initial Public Offering and the sale of the Private Units (the “Trust Account”), (excluding any deferred underwriting commissions and taxes payable on interest earned on the Trust Account) at the time of the signing a definitive agreement in connection with a Business Combination. However, the Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended. There is no assurance that the Company will be able to successfully effect a Business Combination. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company will provide the holders of its Public Shares (“Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. In connection with a proposed Business Combination, the Company may seek shareholder approval of a Business Combination at a meeting called for such purpose at which shareholders may seek to redeem their shares, regardless of whether they vote for or against a Business Combination. The shareholders will be entitled to redeem their shares for a pro rata portion of the amount then in the Trust Account ($10.10 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">The per-share amount</div> to be distributed to shareholders who redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6).</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On March 21, 2019, at the Special Meeting, the Company’s shareholders approved the Company’s amended and restated memorandum and articles of association to extend the date by which the Company has to consummate a Business Combination (the “Extension”) to September 23, 2019 (the “Combination Period”). In connection with the Extension, an aggregate of 13,187,468 ordinary shares was redeemed for an aggregate payment of approximately $136.9 million out of the Trust Account. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If the Company is unable to complete a Business Combination on or before the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than five business days thereafter, redeem 100% of the outstanding Public Shares, at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a per-share price,</div> payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned (net of taxes payable and less interest to pay dissolution expenses up to $50,000), divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the Company’s board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject in each case to its obligations to provide for claims of creditors and the requirements of applicable law. The underwriters have agreed to waive their rights to the deferred underwriting commission held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Company’s Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution (including Trust Account assets) will be less than $10.10 per Unit. The Sponsor has agreed that it will indemnify the Company to the extent necessary to ensure that the proceeds in the Trust Account are not reduced by the claims of target businesses or claims of vendors or other entities that are owed money by the Company for services rendered or contracted for or products sold to the Company, but only if such a vendor or prospective target business does not execute such a waiver. However, the Sponsor may not be able to meet such obligation as the Company has not required its Sponsor to retain any assets to provide for its indemnification obligations, nor has the Company taken any further steps to ensure that the Sponsor will be able to satisfy any indemnification obligations that arise. Moreover, the Sponsor will not be liable to the Public Shareholders if it should fail to satisfy its obligations and instead will only be liable to the Company. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On August 2, 2018, the Company entered into an agreement (“Share Purchase Agreement”) to purchase all of the issued and outstanding shares of capital stock of Medall Healthcare Private Limited, a company registered under the laws of India (“Medall”). On December 3, 2018, the Share Purchase Agreement was terminated automatically. </div></div><div style="text-indent: 4%; font-family: "times new roman"; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On March 15, 2019, the Company issued a press release announcing that it had executed a non-binding Letter of Intent to merge with DermTech, Inc. (“DermTech”), a Delaware corporation and a leading moleculargenomics company, with an initial focus on skin cancer, that develops and markets novel non-invasive diagnostic tests. On May 22, 2019 and May 23, 2019, the Company entered into separate subscription agreements (each an “Initial Subscription Agreement” and, collectively, the “Initial Subscription Agreements”), with new health care focused institutional investors as well as certain existing investors in DermTech (the “Initial Subscribers”), pursuant to which the Initial Subscribers agreed to purchase an aggregate of 6,153,847 shares (the “PIPE Shares”) of the Company’s common stock for a purchase price of $3.25 per share, in a private placement in which the Company will raise an aggregate of approximately $20 million, less certain offering related expenses payable by the Company (the “Private Placement”). The PIPE Shares are identical to the shares of common stock that will be held by the Company’s public stockholders at the time of the closing of the Merger, as defined below. The closing of the sale of PIPE Shares and the Preferred Shares will be contingent upon, among other things, the substantially concurrent consummation of the Merger.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On May 29, 2019, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with DermTech and DT Merger Sub, Inc., a wholly owned subsidiary company of the Company incorporated in Delaware (“Merger Sub”), pursuant to which the Company will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domicile</div> out of the British Virgin Islands and continue as a company incorporated in the State of Delaware and Merger Sub will merge with and into DermTech (the “Merger”), with DermTech surviving the Merger as a wholly owned subsidiary of the Company. Upon the closing of the Merger (the “Merger Closing”), all of DermTech’s outstanding common stock and preferred stock will be cancelled and converted automatically into the right to receive an aggregate of <div style="letter-spacing: 0px; top: 0px;;display:inline;">16,000,000</div> shares of the Company less the total number of shares of the Company’s common stock that can be acquired or received pursuant to certain options, restricted stock units and warrants of DermTech, as set forth in the Merger Agreement. The Merger Agreement also provides that, prior to the Closing, Constellation will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domicile</div> out of the British Virgin Islands and continue as a company incorporated in the State of Delaware (Note 9).</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On August 1, 2019, certain of the Initial Subscribers entered into amended and restated subscription agreements (the “Amended and Restated Subscription Agreements”) pursuant to which the Company agreed to sell to each such subscriber, and each such subscriber agreed to purchase, (i) shares of the Company’s common stock at a purchase price of $3.25 per share and (ii) shares of Series A Convertible Preferred Stock of the Company (the “Preferred Shares”) at a purchase price of $3,250 per Preferred Share. The subscribers to the Amended and Restated Subscription Agreements agreed to purchase an aggregate of 1,230,769 shares of the Company’s common stock and 1,231 Preferred Shares for an aggregate total purchase price of approximately $8 million. Pursuant to the terms of the Amended and Restated Subscription Agreements, each Preferred Share is convertible into 1,000 shares of the Company’s common stock. In connection with the New Subscription Agreement and the proposed issuance of Preferred Shares to certain subscribers, the Company received a waiver from DermTech to certain provisions of the Merger Agreement allowing the Company to (i) issue the Preferred Shares pursuant to the Amended and Restated Subscription Agreements and (ii) increase the amount of the proposed Private Placement to $24 million. On August 1, 2019, certain of the Initial Subscribers entered into an Omnibus Common Share Subscription Agreement Amendment, which modified certain of the Initial Subscription Agreements to, among other things, adjust the limitation on the aggregate proceeds that Constellation is permitted to receive from the sale of its stock from the date of the Merger Agreement from $20 million to $24 million.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On August 1, 2019, the Company entered into a subscription agreement (the “New Subscription Agreement”) with a new investor (the “New Subscriber”), pursuant to which the New Subscriber agreed to purchase, and the Company agreed to sell to the New Subscriber, an aggregate of 1,230,769 shares of the Company’s common stock, at a purchase price of $3.25 per share for a total purchase price of approximately $4 million. Under the New Subscription Agreement, the shares of the Company’s common stock to be issued and the price per share are subject to adjustment for any reverse split or other adjustment that may be effected for the purpose of meeting the initial listing requirements of the Nasdaq Capital Market in connection with the consummation of the Merger. The shares of the Company’s common stock to be issued pursuant to the New Subscription Agreement will be identical to the shares of the Company’s common stock that will be held by the Company’s public stockholders upon the closing of the Transaction.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard</div></div> </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On February 22, 2019, the Company received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with Listing Rule 5550(a)(3) (the “Minimum Public Holders Rule”), which requires the Company to have at least 300 public holders for continued listing on the NASDAQ Capital Market. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the NASDAQ Capital Market. </div></div><div style="font-size: 1px; margin-top: 0px; margin-bottom: 0px; background: none;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-indent: 4%; font-family: "times new roman"; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On April 8, 2019, the Company submitted a plan to regain compliance with the Minimum Public Holders Rule to Nasdaq providing that it expects to regain compliance with the Minimum Public Holders Rule upon the consummation of the Merger. Nasdaq subsequently provided the Company with an extension until August 21, 2019, to demonstrate compliance with Nasdaq’s initial listing requirements. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Going Concern Consideration </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of June 30, 2019, the Company had cash held outside the Trust Account of approximately $15,000, cash and marketable securities held in the Trust Account of approximately $12.4 million (including approximately $438,000 of interest income, net of unrealized losses), substantially all of which is invested in U.S. treasury bills with a maturity of 180 days or less, and a working capital deficit of approximately $2.4 million. Further, the Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. Based on the foregoing, the Company will have insufficient funds available to operate its business through the earlier of consummation of a Business Combination or September 23, 2019. Following the initial Business Combination, if cash on hand is insufficient, the Company will need to obtain additional financing in order to meet its obligations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. The Company’s plans to raise capital or to consummate the initial Business Combination may not be successful. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basis of presentation </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 10 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> of the Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended March 31, 2019 as filed with the SEC on June 14, 2019, which contains the audited consolidated financial statements and notes thereto. The financial information as of June 30, 2019 is derived from the audited consolidated financial statements presented in the Company’s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended March 31, 2019. The interim results for the three months ended June 30, 2019 are not necessarily indicative of the results to be expected for the year ending March 31, 2020 or for any future interim periods.</div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Principles of Consolidation </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The condensed consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. </div><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Emerging growth company </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">to non-emerging growth</div> companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of estimates </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from our estimates. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of June 30, 2019 and March 31, 2019. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash and marketable securities held in Trust Account </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">At June 30, 2019 and March 31, 2019, the assets held in the Trust Account were substantially held in U.S. Treasury Bills. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Concentration of credit risk </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which, at times may exceed the Federal depository insurance coverage of $250,000. The Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. </div><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value of financial instruments </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the accompanying condensed consolidated balance sheets, primarily due to their short-term nature. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary shares subject to possible redemption </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at June 30, 2019 and March 31, 2019, ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ equity section of the Company’s condensed consolidated balance sheets. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net income (loss) per ordinary share </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. The Company applies <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the two-class method</div> in calculating earnings per share. Ordinary shares subject to possible redemption at June 30, 2019 and 2018, which are not currently redeemable and are not redeemable at fair value, have been excluded from the calculation of basic loss per share since such shares, if redeemed, only participate in their pro rata share of the earnings from the assets held in the Trust Account. The Company has not considered the effect of (1) warrants sold in the Initial Public Offering and private placement to purchase 7,468,125 ordinary shares, and (2) rights sold in the Initial Public Offering and private placement that convert into 1,493,625 ordinary shares, in the calculation of diluted loss per share, since the exercise of the warrants and the conversion of rights into ordinary shares is contingent upon the occurrence of future events. As a result, diluted loss per share is the same as basic loss per share for the periods.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reconciliation of net (loss) income per ordinary share </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company’s net (loss) income is adjusted for the portion of income that is attributable to ordinary shares subject to redemption, as these shares only participate in the income of the Trust Account and not the losses of the Company. Accordingly, basic and diluted net (loss) income per ordinary share is calculated as follows: </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px; background: none;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="padding: 0px;;width:74%;"></td><td style="padding: 0px;;vertical-align:bottom;;width:4%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:3%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">For the three months ended June 30,</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net income</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(138,794</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">443,788</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Less: Income attributable to ordinary shares subject to redemption</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">(4,237</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">(562,289</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Adjusted net income (loss)</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(143,031</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(118,501</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">) </td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Weighted average ordinary shares outstanding, basic and diluted</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">5,260,831</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">5,091,071</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Basic and diluted net income (loss) per ordinary share</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(0.03</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(0.02</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">) </div></td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="font-size: 1px; margin-top: 0px; margin-bottom: 0px; background: none;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman"; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The calculation of income attributable to ordinary shares subject to redemption is as follows: </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px; background: none;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: "times new roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="padding: 0px;;width:72%;"></td><td style="padding: 0px;;vertical-align:bottom;;width:8%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;;vertical-align:bottom;;width:7%;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td><td style="padding: 0px;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">For the three months ended June 30,</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2018</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">Income attributable to ordinary shares subject to redemption:</div></div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Interest income and unrealized gains (losses)</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">74,075</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;">$</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">601,958</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Less:</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(i) Company’s portion available to pay taxes</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;text-align:right;;vertical-align:bottom;">—  </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">(ii) Company’s portion available to be withdrawn for working capital purposes</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">—  </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subtotal</div></div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">74,075</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">601,958</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Ordinary shares subject to redemption</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">67,956</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">13,427,259</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total IPO shares</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">1,187,532</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;">14,375,000</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">% Attributable to ordinary shares subject to redemption</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5.72</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">% </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">93.41</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">% </td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="text-indent: -1em; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income Attributable to Ordinary Shares Subject to Redemption</div></div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">4,237</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">562,289</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;;vertical-align:bottom;"> </td></tr><tr style="font-size: 1px;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"> </td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal; background: none;"><div style="text-decoration: none; background: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"> </td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income taxes </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company complies with the accounting and reporting requirements of ASC Topic 740, “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">be more-likely-than-not to</div> be sustained upon examination by taxing authorities. The Company’s management determined that the British Virgin Islands is the Company’s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of June 30, 2019 and March 31, 2019, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company may be subject to potential examination by foreign taxing authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with foreign tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company’s tax provision is zero because the Company is organized in the British Virgin Islands with no connection to any other taxable jurisdiction. As such, the Company has no deferred tax assets. The Company is considered to be an exempted British Virgin Islands Company, and is presently not subject to income taxes or income tax filing requirements in the British Virgin Islands or the United States. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Recently issued accounting standards </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s condensed consolidated financial statements. </div></div><div style="text-indent: 4%; font-family: "times new roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

1230769

1231

3.25

3250

The Series A Certificate of Designation will provide that holders of the Preferred Shares shall participate pari passu with the holders of CNAC common stock on an as-converted basis in the event of dissolution, liquidation or winding up of CNAC. The Series A Certificate of Designation also will provide that each Preferred Share will be convertible into CNAC common stock at a conversion price per share equal to $0.00325, provided that in no event shall any Preferred Shares be convertible if such conversion would result in the holder of such shares beneficially owning more than 9.99% of CNAC’s then-outstanding shares of common stock.

1230769

3.25

20000000

Pursuant to the terms of the Amended and Restated Subscription Agreements, each Preferred Share is convertible into 1,000 shares of the Company’s common stock.

1000

3.25

8000000

4000000

0.00325

20000000

24000000

of which 0.5% is payable solely at the discretion of the Company 10-Q false 2019-06-30 2020 Q1 Constellation Alpha Capital Corp. 0001651944 --03-31 true Accelerated Filer true true false iso4217:USD xbrli:shares xbrli:pure iso4217:USD xbrli:shares Excludes an aggregate of up to 67,956 and 13,427,259 shares subject to possible redemption at June 30, 2019 and 2018, respectively.

EX-101.SCH 7 cnacu-20190630.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 1007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 1008 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - INITIAL PUBLIC OFFERING link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - PRIVATE PLACEMENT link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - SHAREHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - MERGER AGREEMENT link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - SCHEDULE OF EARNINGS PER SHARE, BASIC AND DILUTED (Details) link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - INCOME ATTRIBUTABLE TO ORDINARY SHARES SUBJECT TO REDEMPTION (Details) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - INITIAL PUBLIC OFFERING - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - PRIVATE PLACEMENT - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - RELATED PARTY TRANSACTIONS - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - COMMITMENTS AND CONTINGENCIES- Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - SHAREHOLDERS' EQUITY - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING (Details) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - MERGER AGREEMENT - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - SUBSEQUENT EVENTS - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 cnacu-20190630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 cnacu-20190630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 cnacu-20190630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Document and Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Class of Stock [Domain] Units [Member] Units [Member] Warrant [Member] Warrant [Member] Common Stock [Member] Common Stock [Member] Rights [Member] Rights [Member] Document Information [Line Items] Entity Current Reporting Status Trading Symbol Entity Address, State or Province Entity Interactive Data Current Title of 12(b) Security Security Exchange Name Entity Common Stock, Shares Outstanding Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Shell Company Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Condensed Balancesheet [Abstract] Statement [Table] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash Cash—Beginning Cash—Ending Prepaid Expense, Current Prepaid expenses Assets, Current Total current assets Assets Held-in-trust, Noncurrent Cash and marketable securities held in Trust Account Assets held-in-trust, noncurrent Assets Total assets Liabilities and Equity [Abstract] Liabilities and Shareholders' Equity: Liabilities, Current [Abstract] Current liabilities: Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued expenses Liabilities, Current Total current liabilities Notes and Loans Payable Advances and notes payable Deferred Underwriting Fees, Noncurrent Deferred underwriting fees Underwriting Commision Payable Value of deferred underwriting fees through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date. Liabilities Total liabilities Commitments and Contingencies Commitments and Contingencies Temporary Equity, Carrying Amount, Attributable to Parent Ordinary shares subject to possible redemption, 67,956 and 81,701 shares at redemption values as of June 30, 2019 and March 31, 2019, respectively Stockholders' Equity Attributable to Parent [Abstract] Shareholders' Equity: Preferred Stock, Value, Issued Preferred shares, no par value; unlimited shares authorized; none issued and outstanding Common Stock, Value, Issued Ordinary shares, no par value; unlimited shares authorized; 5,274,576 and 5,260,831 shares issued and outstanding (excluding 67,956 and 81,701 shares subject to possible redemption) as of June 30, 2019 and March 31, 2019, respectively Retained Earnings (Accumulated Deficit) Retained earnings Stockholders' Equity Attributable to Parent Total shareholders' equity Balance Balance Liabilities and Equity Total Liabilities and Shareholders' Equity Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Common Stock, Par or Stated Value Per Share Common Stock, Shares, Issued Common stock, shares, issued Common Stock, Shares, Outstanding Common stock, shares, outstanding Temporary Equity, Shares Outstanding Ordinary shares subject to redemption Income Statement [Abstract] Operating Expenses Operating costs Operating Income (Loss) Loss from operations Other Nonoperating Income (Expense) [Abstract] Other income: Investment Income, Nonoperating Interest income Unrealized Gain (Loss) on Securities Unrealized gain (loss) on marketable securities held in Trust Account Unrealized (gain) loss on securities held in Trust Account Net Income (Loss) Attributable to Parent Net (loss) income Net income Net (loss) income Change in value of deferred underwriting fees liability Reduction of deferred underwriting fee Reduction of deferred underwriting fee Change in value of deferred underwriting fees liability. Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average ordinary shares outstanding, basic and diluted Weighted average ordinary shares outstanding, basic and diluted Earnings Per Share, Basic and Diluted Basic and diluted net loss per ordinary share Basic and diluted net income (loss) per ordinary share Related Party [Axis] Related Party [Domain] Statement of Stockholders' Equity [Abstract] Retained Earnings [Member] Shares, Outstanding Balance (in Shares) Balance (in Shares) Stock Redeemed or Called During Period, Value Change in ordinary shares subject to possible redemption Shares Subject To Redemption Period Increase Decrease Change in ordinary shares subject to possible redemption (in shares) Shares subject to redemption, period increase (decrease). Statement of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] Cash Flows from Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net (loss) income to net cash used in operating activities: Investment Income, Interest Interest earned on marketable securities held in Trust Account Increase (Decrease) in Operating Assets [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense Prepaid expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash Flows from Financing Activities: Proceeds from Related Party Debt Advances received from related party Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net change in cash Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-Cash investing and financing activities: Change In Value Of Ordinary Shares Subject To Possible Redemption Change in value of ordinary shares subject to possible redemption The amount represent Change In Value Of Ordinary Shares Subject To Possible Redemption. Accounts payable paid by related party under the form of promissory notes Accounts payable paid by related party under the form of promissory notes Accounts payable paid by related party under the form of promissory notes. Affiliated Entity [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS Accounting Policies [Abstract] Significant Accounting Policies [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Equity [Abstract] Initial Public Offering Disclosure [Text Block] INITIAL PUBLIC OFFERING The entire disclosure for initial public offering. Private Placement Disclosure [Text Block] PRIVATE PLACEMENT The entire disclosure for private placement. Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] RELATED PARTY TRANSACTIONS Commitments and Contingencies Disclosure [Abstract] Commitments And Contingencies Disclosure[Abstract] Commitments Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES Stockholders' Equity Note [Abstract] Stockholders' Equity Note Disclosure [Text Block] SHAREHOLDERS' EQUITY Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] FAIR VALUE MEASUREMENTS Business Combinations [Abstract] Merger Agreement Disclosure [Text Block] MERGER AGREEMENT Disclosure Of The Merger Agreement Along With The Details of Number of shares To Be Issued To The Transferee Company Subsequent Events [Abstract] Subsequent Events [Text Block] SUBSEQUENT EVENTS Basis of Accounting, Policy [Policy Text Block] Basis of presentation Emerging Growth Company, Policy [Policy Text Block] Emerging growth company Disclosure of accounting policy relating to emerging growth company. Use of Estimates, Policy [Policy Text Block] Use of estimates Cash and Cash Equivalents, Policy [Policy Text Block] Cash and cash equivalents Assets Held In Trust [Policy Text Block] Cash and marketable securities held in Trust Account Assets held in trust policy text block Shares Subject to Mandatory Redemption, Changes in Redemption Value, Policy [Policy Text Block] Ordinary shares subject to possible redemption Income Tax, Policy [Policy Text Block] Income taxes Earnings Per Share, Policy [Policy Text Block] Net income (loss) per ordinary share Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of credit risk Fair Value of Financial Instruments, Policy [Policy Text Block] Fair value of financial instruments New Accounting Pronouncements, Policy [Policy Text Block] Recently issued accounting standards Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule Of Computation Of Income Attributable To ordinary Shares Subject To Redemption [Table Text Block] Tabular disclosure of computation of income attributable to ordinary shares subject to redemption. Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Sale of Stock [Axis] Sale of Stock [Domain] IPO [Member] Private Placement [Member] IPO and Private Placement [Member] Sale of Stock, Number of Shares Issued in Transaction Sale of stock, number of shares issued in transaction Sale of Stock, Price Per Share Sale of stock, price per share Proceeds from Issuance of Private Placement Capital raised through purchase of shares Proceeds from issuance of private placement Capital raised through purchase of shares Dissolution Expenses Dissolution expenses Cost incurred in relation to dissolution during the period. Conversion of Stock, Description Conversion of stock, description Class of Warrant or Right, Exercise Price of Warrants or Rights Class of warrant or right, exercise price of warrants or rights Stock Redeemed or Called During Period, Shares Stock redeemed during period Payments For Redemption Of Ordinary Shares Payment for redemption of ordinary shares Represents Payments For Redemption Of Ordinary Shares. Stock Issued During Period, Shares, New Issues Aggregate no of shares to purchase Aggregate no of shares to purchase Agrgate no of shares to purchase Share Price Common stock purchase price Common stock purchase price Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Right to receive an aggregate of shares of the company Cash Cash held out side trust Interest Income (Expense), Net Interest income (expense), net Investment Company, Distributable Earnings (Loss), Accumulated Capital Loss Carryforward Investment company, distributable earnings (loss), accumulated capital loss carryforward Shares Issued, Price Per Share Shares issued, price per share Convertible Preferred Stock, Shares Issued upon Conversion Shares Issued Upon Conversion Convertible Preferred Stock, Terms of Conversion Description Of The Terms Of Conversion of Convertible Preferred Stock Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Agreement [Axis] Agreement Agreement [Domain] Agreement Subscription Agreement [Member] Subscription Agreement Amended And Restated Subscription Agreement [Member] New Subscription Agreement [Member] PIPE Shares [Member] PIPE Shares Convertible Preferred Stock [Member] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] DermTech [Member] Derm Tech Legal Entity [Axis] Entity [Domain] Merger [Axis] Merger [Domain] Equity Components [Axis] Equity Component [Domain] Range [Axis] Range [Domain] Minimum [Member] Maximum [Member] Modification Type [Axis] Modification Type [Domain] Modification To Agreement [Member] Dilutive Securities, Effect on Basic Earnings Per Share Less: Income attributable to ordinary shares subject to redemption Net Income (Loss) Available to Common Stockholders, Diluted Adjusted net income (loss) Income Attributable To Ordinary Shares Subject To Redemption [Abstract] Heading Disclosing the Non operating income which is available to the shareholders whose shares are to be redeemed. Interest Income And Unrealized Gain Loss On Securities Interest income and unrealized gains (losses) Interest Income And Unrealized Gain (Loss) On Securities Income Tax Expense (Benefit) (i) Company's portion available to pay taxes Working Capital (ii) Company's portion available to be withdrawn for working capital purposes Working Capital Interest Income And Unrealized Gain Loss On Securities Net Subtotal Interest Income And Unrealized Gain (Loss) On Securities, Net Common Stock IPO Shares Outstanding Total IPO shares Common stock, IPO shares, outstanding. Income Attributable To Ordinary Shares Subject To Redemption Income Attributable to Ordinary Shares Subject to Redemption Income attributable to ordinary shares subject to redemption. Percentage Of Ordinary Shares Subject To Redemption % Attributable to ordinary shares subject to redemption Percentage of ordinary shares subject to redemption. Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Public Warrant [Member] Public Right [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from computation of earnings per share, amount Cash, FDIC Insured Amount Cash, FDIC insured amount EX-101.PRE 11 cnacu-20190630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Aug. 13, 2019
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Registrant Name	Constellation Alpha Capital Corp.
Entity Central Index Key	0001651944
Current Fiscal Year End Date	--03-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Address, State or Province	FL
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	true
Entity Common Stock, Shares Outstanding		5,342,532
Units [Member]
Document Information [Line Items]
Title of 12(b) Security	Units, each consisting of one Ordinary Share, one Right and one Warrant
Trading Symbol	CNACU
Security Exchange Name	NASDAQ
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Ordinary Shares
Trading Symbol	CNAC
Security Exchange Name	NASDAQ
Warrant [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants, each Warrant entitling the holder to purchase one-half (1/2) of one Ordinary Share
Trading Symbol	CNACW
Security Exchange Name	NASDAQ
Rights [Member]
Document Information [Line Items]
Title of 12(b) Security	Rights, each Right entitling the holder to receive one-tenth (1/10) of one Ordinary Share
Trading Symbol	CNACR
Security Exchange Name	NASDAQ

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2019	Mar. 31, 2019
Current assets:
Cash	$ 15,282	$ 30,487
Prepaid expenses	45,750	51,257
Total current assets	61,032	81,744
Cash and marketable securities held in Trust Account	12,432,054	12,357,980
Total assets	12,493,086	12,439,724
Current liabilities:
Accounts payable and accrued expenses	2,353,005	1,522,158
Advances and notes payable	116,154	36,095
Total current liabilities	2,469,159	1,558,253
Deferred underwriting fees	4,312,500	5,031,250
Total liabilities	6,781,659	6,589,503
Commitments and Contingencies
Ordinary shares subject to possible redemption, 67,956 and 81,701 shares at redemption values as of June 30, 2019 and March 31, 2019, respectively	711,419	850,217
Shareholders' Equity:
Preferred shares, no par value; unlimited shares authorized; none issued and outstanding	0	0
Ordinary shares, no par value; unlimited shares authorized; 5,274,576 and 5,260,831 shares issued and outstanding (excluding 67,956 and 81,701 shares subject to possible redemption) as of June 30, 2019 and March 31, 2019, respectively	3,340,730	3,201,932
Retained earnings	1,659,278	1,798,072
Total shareholders' equity	5,000,008	5,000,004
Total Liabilities and Shareholders' Equity	$ 12,493,086	$ 12,439,724

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2019	Mar. 31, 2019
Preferred Stock, Par or Stated Value Per Share	$ 0	$ 0
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0	$ 0
Common Stock, Shares, Issued	5,274,576	5,260,831
Common Stock, Shares, Outstanding	5,274,576	5,260,831
Temporary Equity, Shares Outstanding	67,956	81,701

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)

3 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Operating costs

$ 931,619

$ 158,170

Loss from operations

(931,619)

(158,170)

Other income:

Interest income

70,855

649,640

Unrealized gain (loss) on marketable securities held in Trust Account

3,220

(47,682)

Reduction of deferred underwriting fee

718,750

Net (loss) income

$ (138,794)

$ 443,788

Weighted average ordinary shares outstanding, basic and diluted

^[1]

5,260,831

5,091,071

Basic and diluted net loss per ordinary share

$ (0.03)

$ (0.02)

[1]	Excludes an aggregate of up to 67,956 and 13,427,259 shares subject to possible redemption at June 30, 2019 and 2018, respectively.

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - shares	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018
Temporary Equity, Shares Outstanding	67,956	81,701	13,427,259

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)	Total	Common Stock [Member]	Retained Earnings [Member]
Balance at Mar. 31, 2018	$ 5,000,001	$ 4,146,387	$ 853,614
Balance (in Shares) at Mar. 31, 2018		5,091,071
Change in ordinary shares subject to possible redemption	(443,788)	$ (443,788)	0
Change in ordinary shares subject to possible redemption (in shares)		11,670
Net income	443,788	$ 0	443,788
Balance at Jun. 30, 2018	5,000,001	$ 3,702,599	1,297,402
Balance (in Shares) at Jun. 30, 2018		5,102,741
Balance at Mar. 31, 2019	5,000,004	$ 3,201,932	1,798,072
Balance (in Shares) at Mar. 31, 2019		5,260,831
Change in ordinary shares subject to possible redemption	138,798	$ 138,798	0
Change in ordinary shares subject to possible redemption (in shares)		13,745
Net income	(138,794)	$ 0	(138,794)
Balance at Jun. 30, 2019	$ 5,000,008	$ 3,340,730	$ 1,659,278
Balance (in Shares) at Jun. 30, 2019		5,274,576

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 18 R7.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash Flows from Operating Activities:
Net (loss) income	$ (138,794)	$ 443,788
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Interest earned on marketable securities held in Trust Account	(70,854)	(649,640)
Unrealized (gain) loss on securities held in Trust Account	(3,220)	47,682
Reduction of deferred underwriting fee	(718,750)	0
Changes in operating assets and liabilities:
Prepaid expenses	5,507	25,999
Accounts payable and accrued expenses	900,406	67,789
Net cash used in operating activities	(25,705)	(64,382)
Cash Flows from Financing Activities:
Advances received from related party	10,500	0
Net cash provided by financing activities	10,500	0
Net change in cash	(15,205)	(64,382)
Cash—Beginning	30,487	449,942
Cash—Ending	15,282	385,560
Non-Cash investing and financing activities:
Change in value of ordinary shares subject to possible redemption	138,798	443,788
Affiliated Entity [Member]
Non-Cash investing and financing activities:
Accounts payable paid by related party under the form of promissory notes	$ 69,559	$ 0

XML 19 R8.htm IDEA: XBRL DOCUMENT

DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS

3 Months Ended

Jun. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS

1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS

into one-tenth (1/10)

of one ordinary share. Each Public Warrant entitles the holder to

purchase one-half (1/2)

of one ordinary share at an exercise price of $11.50 per whole share.

The per-share amount

to be distributed to shareholders who redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6).

a per-share price,

payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned (net of taxes payable and less interest to pay dissolution expenses up to $50,000), divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the Company’s board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject in each case to its obligations to provide for claims of creditors and the requirements of applicable law. The underwriters have agreed to waive their rights to the deferred underwriting commission held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Company’s Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution (including Trust Account assets) will be less than $10.10 per Unit. The Sponsor has agreed that it will indemnify the Company to the extent necessary to ensure that the proceeds in the Trust Account are not reduced by the claims of target businesses or claims of vendors or other entities that are owed money by the Company for services rendered or contracted for or products sold to the Company, but only if such a vendor or prospective target business does not execute such a waiver. However, the Sponsor may not be able to meet such obligation as the Company has not required its Sponsor to retain any assets to provide for its indemnification obligations, nor has the Company taken any further steps to ensure that the Sponsor will be able to satisfy any indemnification obligations that arise. Moreover, the Sponsor will not be liable to the Public Shareholders if it should fail to satisfy its obligations and instead will only be liable to the Company. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

re-domicile

out of the British Virgin Islands and continue as a company incorporated in the State of Delaware and Merger Sub will merge with and into DermTech (the “Merger”), with DermTech surviving the Merger as a wholly owned subsidiary of the Company. Upon the closing of the Merger (the “Merger Closing”), all of DermTech’s outstanding common stock and preferred stock will be cancelled and converted automatically into the right to receive an aggregate of

16,000,000

shares of the Company less the total number of shares of the Company’s common stock that can be acquired or received pursuant to certain options, restricted stock units and warrants of DermTech, as set forth in the Merger Agreement. The Merger Agreement also provides that, prior to the Closing, Constellation will

re-domicile

out of the British Virgin Islands and continue as a company incorporated in the State of Delaware (Note 9).

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Going Concern Consideration

XML 20 R9.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

10-Q

and Article 10 of Regulation

S-X

of the Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form

10-K

for the year ended March 31, 2019 as filed with the SEC on June 14, 2019, which contains the audited consolidated financial statements and notes thereto. The financial information as of June 30, 2019 is derived from the audited consolidated financial statements presented in the Company’s Annual Report on Form

10-K

for the year ended March 31, 2019. The interim results for the three months ended June 30, 2019 are not necessarily indicative of the results to be expected for the year ending March 31, 2020 or for any future interim periods.

Principles of Consolidation

Emerging growth company

to non-emerging growth

companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of estimates

Cash and cash equivalents

Cash and marketable securities held in Trust Account

At June 30, 2019 and March 31, 2019, the assets held in the Trust Account were substantially held in U.S. Treasury Bills.

Concentration of credit risk

Fair value of financial instruments

Ordinary shares subject to possible redemption

Net income (loss) per ordinary share

Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. The Company applies

the two-class method

in calculating earnings per share. Ordinary shares subject to possible redemption at June 30, 2019 and 2018, which are not currently redeemable and are not redeemable at fair value, have been excluded from the calculation of basic loss per share since such shares, if redeemed, only participate in their pro rata share of the earnings from the assets held in the Trust Account. The Company has not considered the effect of (1) warrants sold in the Initial Public Offering and private placement to purchase 7,468,125 ordinary shares, and (2) rights sold in the Initial Public Offering and private placement that convert into 1,493,625 ordinary shares, in the calculation of diluted loss per share, since the exercise of the warrants and the conversion of rights into ordinary shares is contingent upon the occurrence of future events. As a result, diluted loss per share is the same as basic loss per share for the periods.

Reconciliation of net (loss) income per ordinary share


	For the three months ended June 30,
	2019			2018
Net income	$	(138,794	)	$	443,788
Less: Income attributable to ordinary shares subject to redemption		(4,237	)		(562,289	)

Adjusted net income (loss)	$	(143,031	)	$	(118,501	)

Weighted average ordinary shares outstanding, basic and diluted		5,260,831			5,091,071

Basic and diluted net income (loss) per ordinary share	$	(0.03	)	$	(0.02	)

The calculation of income attributable to ordinary shares subject to redemption is as follows:


	For the three months ended June 30,
	2019			2018
Income attributable to ordinary shares subject to redemption:
Interest income and unrealized gains (losses)	$	74,075		$	601,958
Less:
(i) Company’s portion available to pay taxes		—			—
(ii) Company’s portion available to be withdrawn for working capital purposes		—			—

Subtotal		74,075			601,958
Ordinary shares subject to redemption		67,956			13,427,259
Total IPO shares		1,187,532			14,375,000
% Attributable to ordinary shares subject to redemption		5.72	%		93.41	%

Income Attributable to Ordinary Shares Subject to Redemption	$	4,237		$	562,289

Income taxes

be more-likely-than-not to

be sustained upon examination by taxing authorities. The Company’s management determined that the British Virgin Islands is the Company’s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of June 30, 2019 and March 31, 2019, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.

Recently issued accounting standards

XML 21 R10.htm IDEA: XBRL DOCUMENT

INITIAL PUBLIC OFFERING

3 Months Ended

Jun. 30, 2019

Equity [Abstract]

INITIAL PUBLIC OFFERING

3. INITIAL PUBLIC OFFERING

into one-tenth (1/10)

of one ordinary share. Each Public Warrant entitles the holder to

purchase one-half (

) of one ordinary share at an exercise price of $11.50 per whole share. The Company will not issue fractional shares.

XML 22 R11.htm IDEA: XBRL DOCUMENT

PRIVATE PLACEMENT

3 Months Ended

Jun. 30, 2019

Equity [Abstract]

PRIVATE PLACEMENT

4. PRIVATE PLACEMENT

XML 23 R12.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

3 Months Ended

Jun. 30, 2019

RELATED PARTY TRANSACTIONS

5. RELATED PARTY TRANSACTIONS

Administrative Services Arrangement

and March 31, 2019, respectively

Related Party Loans

XML 24 R13.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Jun. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

6. COMMITMENTS AND CONTINGENCIES

Registration Rights

applicable lock-up period.

The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

The underwriters are entitled to a deferred fee of up to three

and one-half percent

(

3.5

)

of the gross proceeds of the Initial Public Offering, of which 0.5% is payable solely at the discretion of the Company. In May 2019, the Company elected not to pay the 0.5% discretionary deferred underwriting fees to the underwriters. In connection with the execution of the Merger Agreement, CNAC, DermTech and Cowen and Company, LLC (“Cowen”) entered into a letter agreement, dated May 29, 2019, (the “Deferred Underwriting Fee Assignment Agreement”), pursuant to which CNAC agreed to assign to DermTech, and DermTech agreed to assume, CNAC’s obligation under the Underwriting Agreement, dated as of June 19, 2017 (the “Underwriting Agreement”), by and among CNAC and Cowen, acting as representative of the underwriters named in Schedule A thereto (the “Underwriters”), to pay the Underwriters the underwriting fee set forth therein (the “Underwriting Fee Assignment”), subject to certain adjustments and pursuant to the terms of the Deferred Underwriting Fee Assignment Agreement.

one-year

anniversary of the Merger Closing, excluding the proceeds received from any financing consummated prior to or simultaneous with the Merger Closing, then DermTech will pay to the underwriters $2,187,500 within two business days of CNAC receiving the proceeds from such equity financings. If CNAC fails to raise such funds by the

one-year

anniversary of the consummation of the Merger, then DermTech will pay to the Underwriters $1,093,750 within one week of the

one-year

anniversary of the Merger Closing, and the underwriters will have the option to receive an additional $1,093,750 in CNAC common stock at that time (the “Equity Payment”) based on the then fair market value of CNAC common stock, or to receive $1,093,750 in cash at a later date. DermTech’s payment to the Underwriters of $2,187,500, or its payment of $1,093,750 plus the Equity Payment, in either case, shall satisfy DermTech’s obligation to pay the deferred underwriting fees in full, and no further payment of any kind shall be required of DermTech or CNAC in connection with the deferred underwriting fees.

. CNAC has elected not to pay the 0.5% discretionary underwriting discount under the terms of the Underwriting Agreement.

XML 25 R14.htm IDEA: XBRL DOCUMENT

SHAREHOLDERS' EQUITY

3 Months Ended

Jun. 30, 2019

Stockholders' Equity Note [Abstract]

SHAREHOLDERS' EQUITY

7. SHAREHOLDERS’ EQUITY

Preferred Shares

– The Company is authorized to issue an unlimited number of no par value preferred shares, divided into five classes, Class A through Class E, each with such designation, rights and preferences as may be determined by a resolution of the Company’s board of directors to amend the Memorandum and Articles of Association to create such designations, rights and preferences. The Company has five classes of preferred shares to give the Company flexibility as to the terms on which each Class is issued. All shares of a single class must be issued with the same rights and obligations. Accordingly, starting with five classes of preferred shares will allow the Company to issue shares at different times on different terms. At June 30, 2019 and March 31, 2019, there are no preferred shares designated, issued or outstanding.

Ordinary Shares

– The Company is authorized to issue an unlimited number of no par value ordinary shares. Holders of the Company’s ordinary shares are entitled to one vote for each share. At June 30, 2019 and March 31, 2019, there were 5,274,576 and 5,260,831 ordinary shares issued and outstanding (excluding 67,956 and 81,701 ordinary shares subject to possible redemption, respectively).

any 30- trading

day period commencing after a Business Combination, and with respect to the remaining 50% of the Cowen Shares, upon one year after the date of the consummation of a Business Combination, or earlier, in each case, if, subsequent to a Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of the Company’s shareholders having the right to exchange their ordinary shares for cash, securities or other property. In addition, Cowen Investments has agreed (i) to waive its redemption rights with respect to such shares in connection with the completion of a Business Combination and (ii) to waive its rights to liquidating distributions from the Trust Account with respect to such shares if the Company fails to complete a Business Combination within the Combination Period.

Rights

– Each holder of a right will

receive one-tenth (1/10)

of one ordinary share upon consummation of a Business Combination, even if the holder of such right redeemed all shares held by it in connection with a Business Combination. No fractional shares will be issued upon exchange of the rights. No additional consideration will be required to be paid by a holder of rights in order to receive its additional shares upon consummation of a Business Combination as the consideration related thereto has been included in the Unit purchase price paid for by investors in the Initial Public Offering. If the Company enters into a definitive agreement for a Business Combination in which the Company will not be the surviving entity, the definitive agreement will provide for the holders of rights to receive the same per share consideration the holders of the ordinary shares will receive in the transaction on

an as-converted into

ordinary share basis and each holder of a right will be required to affirmatively convert its rights in order to receive 1/10 share underlying each right (without paying additional consideration). The shares issuable upon exchange of the rights will be freely tradable (except to the extent held by affiliates of the Company).

Warrants

– Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the consummation of a Business Combination. No Public Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the ordinary shares issuable upon exercise of the Public Warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the ordinary shares issuable upon the exercise of the Public Warrants is not effective within 90 days from the consummation of a Business Combination, the holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise the Public Warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their Public Warrants on a cashless basis. The Public Warrants will expire five years from the consummation of a Business Combination or earlier upon redemption or liquidation.

The Company may call the warrants for redemption (excluding the Private Warrants):

•

in whole and not in part;

•

at a price of $0.01 per warrant;

•

at any time while the Public Warrants are exercisable;

•

upon not less than 30 days’ prior written notice of redemption to each Public Warrant holder;

•

if, and only if, there is a current registration statement in effect with respect to the ordinary shares underlying such warrants at the time of redemption and for the

entire 30-day trading

period referred to above and continuing each day thereafter until the date of redemption.

XML 26 R15.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS

3 Months Ended

Jun. 30, 2019

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

8. FAIR VALUE MEASUREMENTS

The Company follows the guidance in Accounting Standards Codification (“ASC”) 820 for its financial assets and liabilities that

are re-measured

and reported at fair value at each reporting period,

and non-financial assets

and liabilities that

are re-measured and

reported at fair value at least annually.


Level 1:		Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.


Level 2:		Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.

Level 3:		Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.


Description	Level		June 30, 2019		March 31, 2019
Assets:
Marketable securities held in Trust Account		1	$	12,432,054	$	12,357,980

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 27 R16.htm IDEA: XBRL DOCUMENT

MERGER AGREEMENT

3 Months Ended

Jun. 30, 2019

Business Combinations [Abstract]

MERGER AGREEMENT

9. MERGER AGREEMENT

May 29, 2019

the Company, Merger Sub, and DermTech entered into the Merger Agreement, which was amended on August 1, 2019, pursuant to which Merger Sub will merge with and into DermTech, with DermTech surviving the Merger as a wholly owned subsidiary of CNAC (collectively with the transactions related thereto, the “Transaction”).

Merger Agreement

Domestication

The Merger Agreement provides that at least two business days prior to the Merger Closing, CNAC will

re-domicile

out of the British Virgin Islands and continue as a company incorporated in the

State of Delaware pursuant

to Section 184 of the BVI Business Companies Act and Section 388 of the Delaware General Corporation Law (the “Domestication”). In connection with the Domestication, all ordinary shares of CNAC will be deemed to be converted into shares of common stock, par value $

0.0001

per share, of CNAC (the “CNAC common stock”).

The Transaction and Consideration

At the Merger Closing, all of DermTech’s outstanding common stock and preferred stock will be cancelled and converted automatically into the right to receive an aggregate of

16,000,000

shares of CNAC common stock less the total number of shares of CNAC common stock that can be acquired or received pursuant to certain options, restricted stock units and warrants of DermTech, as set forth in the Merger Agreement. All of DermTech’s options, restricted stock units and warrants, whether vested or unvested, that will remain outstanding following the Merger Closing, will be assumed by CNAC and will become awards to acquire shares of CNAC common stock, as set forth in the Merger Agreement.

Conditions to Completion of the Transaction

Termination of the Merger Agreement

non-appealable

order that has the effect of making consummation of the Merger illegal

Registration Rights Agreement

S-3

to register the resale by the Investors of CNAC common stock issuable in connection with the Transaction. The Registration Rights Agreement will also provide the Investors with demand, “piggy-back” and Form

S-3

registration rights, subject to certain minimum requirements and customary conditions.

Lock-Up

Agreement

Lock-up

Agreement providing each such holder agrees that, during the period commencing on the Merger Closing and continuing to and including the date 180 days after the date of the Merger Closing, such holder will not sell, offer to sell, pledge, or transfer any CNAC securities held by such holder, subject to certain limited exceptions.

Subscription Agreements

No fees or other compensation was paid or will be payable to any of the Subscribers or any third parties in consideration of the Subscribers entering into the Subscription Agreements.

Forfeiture Agreement

XML 28 R17.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

3 Months Ended

Jun. 30, 2019

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

10. SUBSEQUENT EVENTS

New Subscription Agreement

Amended and Restated Subscription Agreements

Omnibus Common Share Subscription Agreement Amendment

First Amendment to Agreement and Plan of Merger

Related Party Loan

XML 29 R18.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Basis of presentation

10-Q

and Article 10 of Regulation

S-X

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form

10-K

Emerging growth company

to non-emerging growth

Use of estimates

Cash and cash equivalents

Cash and marketable securities held in Trust Account

At June 30, 2019 and March 31, 2019, the assets held in the Trust Account were substantially held in U.S. Treasury Bills.

Concentration of credit risk

Fair value of financial instruments

Ordinary shares subject to possible redemption

Net income (loss) per ordinary share

Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. The Company applies

the two-class method

Reconciliation of net (loss) income per ordinary share


	For the three months ended June 30,
	2019			2018
Net income	$	(138,794	)	$	443,788
Less: Income attributable to ordinary shares subject to redemption		(4,237	)		(562,289	)

Adjusted net income (loss)	$	(143,031	)	$	(118,501	)

Weighted average ordinary shares outstanding, basic and diluted		5,260,831			5,091,071

Basic and diluted net income (loss) per ordinary share	$	(0.03	)	$	(0.02	)

The calculation of income attributable to ordinary shares subject to redemption is as follows:


	For the three months ended June 30,
	2019			2018
Income attributable to ordinary shares subject to redemption:
Interest income and unrealized gains (losses)	$	74,075		$	601,958
Less:
(i) Company’s portion available to pay taxes		—			—
(ii) Company’s portion available to be withdrawn for working capital purposes		—			—

Subtotal		74,075			601,958
Ordinary shares subject to redemption		67,956			13,427,259
Total IPO shares		1,187,532			14,375,000
% Attributable to ordinary shares subject to redemption		5.72	%		93.41	%

Income Attributable to Ordinary Shares Subject to Redemption	$	4,237		$	562,289

Income taxes

be more-likely-than-not to

Recently issued accounting standards

XML 30 R19.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

Accordingly, basic and diluted net (loss) income per ordinary share is calculated as follows:


	For the three months ended June 30,
	2019			2018
Net income	$	(138,794	)	$	443,788
Less: Income attributable to ordinary shares subject to redemption		(4,237	)		(562,289	)

Adjusted net income (loss)	$	(143,031	)	$	(118,501	)

Weighted average ordinary shares outstanding, basic and diluted		5,260,831			5,091,071

Basic and diluted net income (loss) per ordinary share	$	(0.03	)	$	(0.02	)

Schedule Of Computation Of Income Attributable To ordinary Shares Subject To Redemption [Table Text Block]

The calculation of income attributable to ordinary shares subject to redemption is as follows:


	For the three months ended June 30,
	2019			2018
Income attributable to ordinary shares subject to redemption:
Interest income and unrealized gains (losses)	$	74,075		$	601,958
Less:
(i) Company’s portion available to pay taxes		—			—
(ii) Company’s portion available to be withdrawn for working capital purposes		—			—

Subtotal		74,075			601,958
Ordinary shares subject to redemption		67,956			13,427,259
Total IPO shares		1,187,532			14,375,000
% Attributable to ordinary shares subject to redemption		5.72	%		93.41	%

Income Attributable to Ordinary Shares Subject to Redemption	$	4,237		$	562,289

XML 31 R20.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Jun. 30, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]


Description	Level		June 30, 2019		March 31, 2019
Assets:
Marketable securities held in Trust Account		1	$	12,432,054	$	12,357,980

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

XML 32 R21.htm IDEA: XBRL DOCUMENT

DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS - Additional Information (Detail) - USD ($)			1 Months Ended				3 Months Ended
	Aug. 01, 2019	May 29, 2019	May 22, 2019	Mar. 21, 2019	Jun. 30, 2017	Jun. 23, 2017	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019
Capital raised through purchase of shares						$ 5,612,500	$ 0	$ 5,612,500
Dissolution expenses						$ 50,000
Conversion of stock, description					Each holder of a right will receive one-tenth (1/10) of one ordinary share upon consummation of a Business Combination, even if the holder of such right redeemed all shares held by it in connection with a Business Combination.	Each Unit consists of one Public Share, one right and one redeemable warrant (“Public Warrant”). Each right will convert into one-tenth (1/10) of one ordinary share. Each Public Warrant entitles the holder to purchase one-half (1/2) of one ordinary share at an exercise price of $11.50 per whole share.
Class of warrant or right, exercise price of warrants or rights						$ 11.50
Stock redeemed during period				13,187,468
Payment for redemption of ordinary shares				$ 136,900,000
Cash held out side trust							15,000
Assets held-in-trust, noncurrent							12,432,054		$ 12,357,980
Interest income (expense), net							438,000
Investment company, distributable earnings (loss), accumulated capital loss carryforward							$ 2,400,000
DermTech [Member]
Right to receive an aggregate of shares of the company		16,000,000
Subscription Agreement [Member] \| PIPE Shares [Member]
Capital raised through purchase of shares			$ 20,000,000
Aggregate no of shares to purchase			6,153,847
Common stock purchase price			$ 3.25
Subsequent Event [Member] \| Amended And Restated Subscription Agreement [Member]
Capital raised through purchase of shares	$ 8,000,000
Convertible Preferred Stock, Terms of Conversion	The Series A Certificate of Designation will provide that holders of the Preferred Shares shall participate pari passu with the holders of CNAC common stock on an as-converted basis in the event of dissolution, liquidation or winding up of CNAC. The Series A Certificate of Designation also will provide that each Preferred Share will be convertible into CNAC common stock at a conversion price per share equal to $0.00325, provided that in no event shall any Preferred Shares be convertible if such conversion would result in the holder of such shares beneficially owning more than 9.99% of CNAC’s then-outstanding shares of common stock.
Subsequent Event [Member] \| Amended And Restated Subscription Agreement [Member] \| Minimum [Member] \| Modification To Agreement [Member]
Capital raised through purchase of shares	$ 20,000,000
Subsequent Event [Member] \| Amended And Restated Subscription Agreement [Member] \| Maximum [Member] \| Modification To Agreement [Member]
Capital raised through purchase of shares	$ 24,000,000
Subsequent Event [Member] \| Amended And Restated Subscription Agreement [Member] \| Common Stock [Member]
Aggregate no of shares to purchase	1,230,769
Common stock purchase price	$ 3.25
Subsequent Event [Member] \| Amended And Restated Subscription Agreement [Member] \| PIPE Shares [Member]
Common stock purchase price	$ 3.25
Subsequent Event [Member] \| Amended And Restated Subscription Agreement [Member] \| Convertible Preferred Stock [Member]
Aggregate no of shares to purchase	1,231
Common stock purchase price	$ 3,250
Shares Issued Upon Conversion	1,000
Convertible Preferred Stock, Terms of Conversion	Pursuant to the terms of the Amended and Restated Subscription Agreements, each Preferred Share is convertible into 1,000 shares of the Company’s common stock.
Subsequent Event [Member] \| New Subscription Agreement [Member] \| Common Stock [Member]
Capital raised through purchase of shares	$ 4,000,000
Aggregate no of shares to purchase	1,230,769
Common stock purchase price	$ 3.25
IPO [Member]
Sale of stock, number of shares issued in transaction						14,375,000
Sale of stock, price per share						$ 10.00
Shares issued, price per share						$ 10.10
Private Placement [Member]
Sale of stock, number of shares issued in transaction						561,250
Capital raised through purchase of shares						$ 5,612,500
IPO and Private Placement [Member]
Sale of stock, price per share						$ 10.10

XML 33 R22.htm IDEA: XBRL DOCUMENT

SCHEDULE OF EARNINGS PER SHARE, BASIC AND DILUTED (Details) - USD ($)

3 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Net income

$ (138,794)

$ 443,788

Less: Income attributable to ordinary shares subject to redemption

(4,237)

(562,289)

Adjusted net income (loss)

$ (143,031)

$ (118,501)

Weighted average ordinary shares outstanding, basic and diluted

^[1]

5,260,831

5,091,071

Basic and diluted net income (loss) per ordinary share

$ (0.03)

$ (0.02)

[1]	Excludes an aggregate of up to 67,956 and 13,427,259 shares subject to possible redemption at June 30, 2019 and 2018, respectively.

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 34 R23.htm IDEA: XBRL DOCUMENT

INCOME ATTRIBUTABLE TO ORDINARY SHARES SUBJECT TO REDEMPTION (Details) - USD ($)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019
Income Attributable To Ordinary Shares Subject To Redemption [Abstract]
Interest income and unrealized gains (losses)	$ 74,075	$ 601,958
(i) Company's portion available to pay taxes	0	0
(ii) Company's portion available to be withdrawn for working capital purposes	0	0
Subtotal	$ 74,075	$ 601,958
Ordinary shares subject to redemption	67,956	13,427,259	81,701
Total IPO shares	1,187,532	14,375,000
% Attributable to ordinary shares subject to redemption	$ 5.72	$ 93.41
Income Attributable to Ordinary Shares Subject to Redemption	$ 4,237	$ 562,289

XML 35 R24.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) - USD ($)	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash, FDIC insured amount	$ 250,000
Public Warrant [Member]
Antidilutive securities excluded from computation of earnings per share, amount	7,468,125
Public Right [Member]
Antidilutive securities excluded from computation of earnings per share, amount		1,493,625

XML 36 R25.htm IDEA: XBRL DOCUMENT

INITIAL PUBLIC OFFERING - Additional Information (Detail)	1 Months Ended
	Jun. 23, 2017 $ / shares shares
Class of warrant or right, exercise price of warrants or rights	$ 11.50
IPO [Member]
Sale of stock, number of shares issued in transaction \| shares	14,375,000
Sale of stock, price per share	$ 10.00
Over-Allotment Option [Member]
Sale of stock, number of shares issued in transaction \| shares	1,875,000
Sale of stock, price per share	$ 10.00

XML 37 R26.htm IDEA: XBRL DOCUMENT

PRIVATE PLACEMENT - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Jun. 23, 2017	Jun. 30, 2019	Jun. 30, 2018
Proceeds from issuance of private placement	$ 5,612,500	$ 0	$ 5,612,500
Private Placement [Member]
Sale of stock, number of shares issued in transaction	561,250
Proceeds from issuance of private placement	$ 5,612,500
Private Placement [Member] \| Cowen Investment [Member]
Sale of stock, number of shares issued in transaction	136,250
Private Placement [Member] \| Sponsor [Member]
Sale of stock, number of shares issued in transaction	425,000

XML 38 R27.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS - Additional Information (Detail) - USD ($)		1 Months Ended		3 Months Ended		12 Months Ended
	Aug. 07, 2019	Mar. 31, 2018	Jun. 20, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	May 21, 2019	Apr. 17, 2019	Mar. 31, 2019
Advances from related parties for expenses incurred		$ 11,100	$ 10,000
Professional fee				$ 30,000	$ 30,000
Chief Executive Officer [Member]
Advances from CEO				10,500		$ 25,000
Subsequent Event [Member] \| Chief Executive Officer [Member]
Due to related parties, current	$ 60,000
Advances from CEO	$ 24,500
Accounts Payable [Member]
Accrued professional fee				100,000					$ 70,000
Commercial Paper [Member]
Debt instrument face amount							$ 14,559	$ 55,000
Commercial Paper [Member] \| Cowen Investments II LLC [Member]
Debt instrument face amount							$ 14,559	$ 55,000
Promissory Notes [Member]
Debt conversion, original debt, amount				$ 1,500,000
Debt instrument, convertible, conversion price				$ 10.00

XML 39 R28.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES- Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Jun. 19, 2017	Jun. 30, 2019	Mar. 31, 2019
Deferred fee on gross proceeds of initial public offering, percentage	(3.50%)
Underwriting Commision Payable		$ 4,312,500	$ 5,031,250
Underwriters deferred fee payment description		of which 0.5% is payable solely at the discretion of the Company
Deferred Underwriting Fee Assignment Agreement [Member]
Proceeds From Equity Financing		$ 15,000,000
DermTech [Member]
Underwriting Commision Payable		$ 2,187,500
DermTech [Member] \| Deferred Underwriting Fee Assignment Agreement [Member]
Deferred underwriting fee payment terms		Pursuant to the terms of the Deferred Underwriting Fee Assignment Agreement, if the Merger is consummated and CNAC raises at least $15.0 million in proceeds from equity financings consummated prior to the one-year anniversary of the Merger Closing, excluding the proceeds received from any financing consummated prior to or simultaneous with the Merger Closing, then DermTech will pay to the underwriters $2,187,500 within two business days of CNAC receiving the proceeds from such equity financings. If CNAC fails to raise such funds by the one-year anniversary of the consummation of the Merger, then DermTech will pay to the Underwriters $1,093,750 within one week of the one-year anniversary of the Merger Closing, and the underwriters will have the option to receive an additional $1,093,750 in CNAC common stock at that time (the "Equity Payment") based on the then fair market value of CNAC common stock, or to receive $1,093,750 in cash at a later date. DermTech's payment to the Underwriters of $2,187,500, or its payment of $1,093,750 plus the Equity Payment, in either case, shall satisfy DermTech's obligation to pay the deferred underwriting fees in full, and no further payment of any kind shall be required of DermTech or CNAC in connection with the deferred underwriting fees.

XML 40 R29.htm IDEA: XBRL DOCUMENT

SHAREHOLDERS' EQUITY - Additional Information (Detail) - USD ($)	1 Months Ended
	Jun. 30, 2017	Jun. 23, 2017	Jun. 30, 2019	Mar. 31, 2019
Common stock, shares, issued			5,274,576	5,260,831
Common stock, shares, outstanding			5,274,576	5,260,831
Financial instruments subject to mandatory redemption, settlement terms, number of shares			67,956	81,701
Founder Shares Forfeited	136,250
Stock Issued	$ 1,362,500
Conversion of Stock, Description	Each holder of a right will receive one-tenth (1/10) of one ordinary share upon consummation of a Business Combination, even if the holder of such right redeemed all shares held by it in connection with a Business Combination.	Each Unit consists of one Public Share, one right and one redeemable warrant (“Public Warrant”). Each right will convert into one-tenth (1/10) of one ordinary share. Each Public Warrant entitles the holder to purchase one-half (1/2) of one ordinary share at an exercise price of $11.50 per whole share.
Warrants and Rights Subject to Mandatory Redemption [Member]
Class Of Warrant Or Right Redemption Price Of Warrants Or Rights	$ 0.01
Cowen Shares Agreement [Member]
Share Price	$ 12.50
Cowen Investment [Member]
Shares Transfer Terms And Conditions	Cowen Investments has agreed not to transfer, assign or sell any of the Cowen Shares (except to certain permitted transferees) until, with respect to 50% of the Cowen Shares, the earlier of (i) one year after the date of the consummation of a Business Combination, or (ii) the date on which the closing price of the Company’s ordinary shares equals or exceeds $12.50 per share for any 20 trading days within any 30- trading day period commencing after a Business Combination, and with respect to the remaining 50% of the Cowen Shares, upon one year after the date of the consummation of a Business Combination, or earlier, in each case, if, subsequent to a Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of the Company’s shareholders having the right to exchange their ordinary shares for cash, securities or other property.

XML 41 R30.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING (Details) - USD ($)	Jun. 30, 2019	Mar. 31, 2019
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Marketable securities held in Trust Account	$ 12,432,054	$ 12,357,980

XML 42 R31.htm IDEA: XBRL DOCUMENT

MERGER AGREEMENT - Additional Information (Detail) - USD ($)	1 Months Ended			3 Months Ended
	Jun. 30, 2019	May 22, 2019	Jun. 23, 2017	Jun. 30, 2019	Jun. 30, 2018
Capital raised through purchase of shares			$ 5,612,500	$ 0	$ 5,612,500
PIPE Shares [Member]
No Of Shares Forfeited On Account Of Sponsoror	2,694,779
PIPE Shares [Member] \| Subscription Agreement [Member]
Aggregate no of shares to purchase		6,153,847
Common stock purchase price		$ 3.25
Capital raised through purchase of shares		$ 20,000,000

XML 43 R32.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS - Additional Information (Detail) - USD ($)			1 Months Ended	3 Months Ended		12 Months Ended
	Aug. 07, 2019	Aug. 01, 2019	Jun. 23, 2017	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Capital raised through purchase of shares			$ 5,612,500	$ 0	$ 5,612,500
Chief Executive Officer [Member]
Advances from CEO				$ 10,500		$ 25,000
Subsequent Event [Member] \| Chief Executive Officer [Member]
Advances from CEO	$ 24,500
Notes Payable To CEO	$ 60,000
Subsequent Event [Member] \| Amended And Restated Subscription Agreement [Member]
Capital raised through purchase of shares		$ 8,000,000
Description Of The Terms Of Conversion of Convertible Preferred Stock		The Series A Certificate of Designation will provide that holders of the Preferred Shares shall participate pari passu with the holders of CNAC common stock on an as-converted basis in the event of dissolution, liquidation or winding up of CNAC. The Series A Certificate of Designation also will provide that each Preferred Share will be convertible into CNAC common stock at a conversion price per share equal to $0.00325, provided that in no event shall any Preferred Shares be convertible if such conversion would result in the holder of such shares beneficially owning more than 9.99% of CNAC’s then-outstanding shares of common stock.
Convertible Stock Conversion Price Per Share		$ 0.00325
Subsequent Event [Member] \| Amended And Restated Subscription Agreement [Member] \| Minimum [Member] \| Modification To Agreement [Member]
Capital raised through purchase of shares		$ 20,000,000
Subsequent Event [Member] \| Amended And Restated Subscription Agreement [Member] \| Maximum [Member] \| Modification To Agreement [Member]
Capital raised through purchase of shares		$ 24,000,000
Subsequent Event [Member] \| Amended And Restated Subscription Agreement [Member] \| Common Stock [Member]
Agrgate no of shares to purchase		1,230,769
Common stock purchase price		$ 3.25
Subsequent Event [Member] \| New Subscription Agreement [Member] \| Common Stock [Member]
Agrgate no of shares to purchase		1,230,769
Common stock purchase price		$ 3.25
Capital raised through purchase of shares		$ 4,000,000
PIPE Shares [Member] \| Subsequent Event [Member] \| Amended And Restated Subscription Agreement [Member]
Common stock purchase price		$ 3.25
Convertible Preferred Stock [Member] \| Subsequent Event [Member] \| Amended And Restated Subscription Agreement [Member]
Agrgate no of shares to purchase		1,231
Common stock purchase price		$ 3,250
Description Of The Terms Of Conversion of Convertible Preferred Stock		Pursuant to the terms of the Amended and Restated Subscription Agreements, each Preferred Share is convertible into 1,000 shares of the Company’s common stock.
Shares Issued Upon Conversion		1,000

EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 76 213 1 true 36 0 false 4 false false R1.htm 1001 - Document - Document and Entity Information Sheet http://wpb.org/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://wpb.org/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://wpb.org/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://wpb.org/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Sheet http://wpb.org/role/CondensedConsolidatedStatementsOfOperationsParenthetical CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Statements 5 false false R6.htm 1006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY Sheet http://wpb.org/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY Statements 6 false false R7.htm 1007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://wpb.org/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 1008 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS Sheet http://wpb.org/role/DescriptionOfOrganizationAndBusinessOperations DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS Notes 8 false false R9.htm 1009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://wpb.org/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 1010 - Disclosure - INITIAL PUBLIC OFFERING Sheet http://wpb.org/role/InitialPublicOffering INITIAL PUBLIC OFFERING Notes 10 false false R11.htm 1011 - Disclosure - PRIVATE PLACEMENT Sheet http://wpb.org/role/PrivatePlacement PRIVATE PLACEMENT Notes 11 false false R12.htm 1012 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://wpb.org/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 12 false false R13.htm 1013 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://wpb.org/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 1014 - Disclosure - SHAREHOLDERS' EQUITY Sheet http://wpb.org/role/ShareholdersEquity SHAREHOLDERS' EQUITY Notes 14 false false R15.htm 1015 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://wpb.org/role/FairValueMeasurements FAIR VALUE MEASUREMENTS Notes 15 false false R16.htm 1016 - Disclosure - MERGER AGREEMENT Sheet http://wpb.org/role/MergerAgreement MERGER AGREEMENT Notes 16 false false R17.htm 1017 - Disclosure - SUBSEQUENT EVENTS Sheet http://wpb.org/role/SubsequentEvents SUBSEQUENT EVENTS Notes 17 false false R18.htm 1018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://wpb.org/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 18 false false R19.htm 1019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://wpb.org/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://wpb.org/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 1020 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://wpb.org/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://wpb.org/role/FairValueMeasurements 20 false false R21.htm 1021 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS - Additional Information (Detail) Sheet http://wpb.org/role/DescriptionOfOrganizationAndBusinessOperationsAdditionalInformationDetail DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS - Additional Information (Detail) Details 21 false false R22.htm 1022 - Disclosure - SCHEDULE OF EARNINGS PER SHARE, BASIC AND DILUTED (Details) Sheet http://wpb.org/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails SCHEDULE OF EARNINGS PER SHARE, BASIC AND DILUTED (Details) Details 22 false false R23.htm 1023 - Disclosure - INCOME ATTRIBUTABLE TO ORDINARY SHARES SUBJECT TO REDEMPTION (Details) Sheet http://wpb.org/role/IncomeAttributableToOrdinarySharesSubjectToRedemptionDetails INCOME ATTRIBUTABLE TO ORDINARY SHARES SUBJECT TO REDEMPTION (Details) Details 23 false false R24.htm 1024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) Sheet http://wpb.org/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) Details 24 false false R25.htm 1025 - Disclosure - INITIAL PUBLIC OFFERING - Additional Information (Detail) Sheet http://wpb.org/role/InitialPublicOfferingAdditionalInformationDetail INITIAL PUBLIC OFFERING - Additional Information (Detail) Details 25 false false R26.htm 1026 - Disclosure - PRIVATE PLACEMENT - Additional Information (Detail) Sheet http://wpb.org/role/PrivatePlacementAdditionalInformationDetail PRIVATE PLACEMENT - Additional Information (Detail) Details 26 false false R27.htm 1027 - Disclosure - RELATED PARTY TRANSACTIONS - Additional Information (Detail) Sheet http://wpb.org/role/RelatedPartyTransactionsAdditionalInformationDetail RELATED PARTY TRANSACTIONS - Additional Information (Detail) Details 27 false false R28.htm 1028 - Disclosure - COMMITMENTS AND CONTINGENCIES- Additional Information (Detail) Sheet http://wpb.org/role/CommitmentsAndContingenciesAdditionalInformationDetail COMMITMENTS AND CONTINGENCIES- Additional Information (Detail) Details 28 false false R29.htm 1029 - Disclosure - SHAREHOLDERS' EQUITY - Additional Information (Detail) Sheet http://wpb.org/role/ShareholdersEquityAdditionalInformationDetail SHAREHOLDERS' EQUITY - Additional Information (Detail) Details 29 false false R30.htm 1030 - Disclosure - FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING (Details) Sheet http://wpb.org/role/FairValueMeasurementsRecurringAndNonrecurringDetails FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING (Details) Details 30 false false R31.htm 1031 - Disclosure - MERGER AGREEMENT - Additional Information (Detail) Sheet http://wpb.org/role/MergerAgreementAdditionalInformationDetail MERGER AGREEMENT - Additional Information (Detail) Details 31 false false R32.htm 1032 - Disclosure - SUBSEQUENT EVENTS - Additional Information (Detail) Sheet http://wpb.org/role/SubsequentEventsAdditionalInformationDetail SUBSEQUENT EVENTS - Additional Information (Detail) Details 32 false false All Reports Book All Reports cnacu-20190630.xml cnacu-20190630.xsd cnacu-20190630_cal.xml cnacu-20190630_def.xml cnacu-20190630_lab.xml cnacu-20190630_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 49 0001193125-19-219949-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-19-219949-xbrl.zip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

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company